Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1H-naphtho[2,3-d]imidazol-2-yl)methyl 4-aminobenzoate
(1R,2R,3R,5S)-2,3,5-trihydroxy-5-(propylcarbamoyl)cyclohexyl (4E)-6-[4-(acetyloxy)-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
-
(1S,3R,4S,5R)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid
-
(2-methoxy-4-nitrophenyl)methylene diacetate
-
(2-[acetyl[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 785 nM
(2-[formyl[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 749 nM
(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methyl)amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: above 0.001 mM
(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methylsulfonyl)amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 498 nM
(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](sulfamoyl)amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 93 nM
(2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 499 nM
(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methyl)amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 132 nM
(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](methylsulfonyl)amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 68 nM
(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl](sulfamoyl)amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 24 nM
(2-[[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonic acid
-
isozyme IMPDH II IC50: 13 nM
(2E)-3-furan-2-yl-N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]prop-2-enamide
(2E)-3-furan-2-yl-N-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]prop-2-enamide
-
isozyme IMPDH II IC50: 0.002 mM
(2E)-3-{3-[N''-cyano-N'-(4-cyano-3-methoxyphenyl)carbamimidamido]phenyl}prop-2-enoic acid
-
(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-enal
-
(2E)-4-[4-(acetyloxy)-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-2-methylbut-2-enoic acid
-
(2E)-4-{6-methoxy-7-methyl-3-oxo-4-[2-(trimethylsilyl)ethoxy]-1,3-dihydro-2-benzofuran-5-yl}-2-methylbut-2-enal
-
(2E)-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-phenylprop-2-enamide
-
(2E)-N-(4-chlorophenyl)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)but-2-enamide
(2E)-N-hydroxy-3-[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]prop-2-enamide
-
(2E)-N-hydroxy-3-[4-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]prop-2-enamide
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(2,3-dihydro-1-benzofuran-7-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(2-acetyl-1-methyl-2,3-dihydro-1H-benzimidazol-4-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(2-methoxyquinoxalin-5-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(2-methyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(2H-1,3-benzodioxol-5-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(3,4-dimethoxybenzene-1-sulfonyl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(3-methoxy-4-methylphenyl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(3-methoxyquinoxalin-5-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(4-cyano-3-methoxyphenyl)carbamoyl]amino}phenyl)ethyl]carbamate
i.e. VX-4997
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(4-methyl-2,3-dihydro-1-benzofuran-6-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(4-oxo-3,4-dihydro-2H-1-benzopyran-6-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(5,6-dihydro-1,4-dioxin-2-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(6,7-dimethoxynaphthalen-1-yl)carbamoyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(E)-1-(3,4-dimethoxyanilino)-2-nitroethenyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[(E)-1-(4-cyano-3-methoxyanilino)-2-nitroethenyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[4-(4-cyano-3-methoxyphenyl)piperazine-1-carbonyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[5-(4-cyano-3-methoxyphenyl)-1H-benzimidazol-2-yl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-(3-{[6-(4-cyano-3-methoxyphenyl)pyrazine-2-carbonyl]amino}phenyl)ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-{3-[2-(3,4-dimethoxyphenoxy)acetamido]phenyl}ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-{3-[2-(4-cyano-3-methoxyphenoxy)acetamido]phenyl}ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-{3-[3-(4-cyano-3-methoxyphenyl)-2,4-dioxoimidazolidin-1-yl]phenyl}ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl [(1S)-1-{3-[N'-(3,4-dimethoxyphenyl)carbamimidamido]phenyl}ethyl]carbamate
-
(2R)-1-cyanobutan-2-yl {(1S)-1-[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]ethyl}carbamate
-
(2R)-1-cyanobutan-2-yl {(1S)-1-[3-({[3-methoxy-4-(morpholin-4-yl)phenyl]carbamoyl}amino)phenyl]ethyl}carbamate
-
(2R)-1-cyanobutan-2-yl {(1S)-1-[3-({[3-methoxy-4-(oxan-4-yl)phenyl]carbamoyl}amino)phenyl]ethyl}carbamate
-
(2R)-1-cyanobutan-2-yl {(1S)-1-[3-({[4-(3,6-dihydro-2H-pyran-4-yl)-3-methoxyphenyl]carbamoyl}amino)phenyl]ethyl}carbamate
-
(2R)-1-cyanobutan-2-yl-[(1S)-1-(3-{[(3,4-dimethoxyphenyl)carbamoyl]amino}phenyl)-ethyl] carbamate
-
(2R)-2-phenyl-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
(2R)-2-[(naphthalen-1-yl)oxy]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
(2S)-1-cyanobutan-2-yl [(1R)-1-(3-{[(3,4-dimethoxyphenyl)carbamothioyl]amino}phenyl)ethyl]carbamate
-
(2S)-1-cyanobutan-2-yl [(1R)-1-(3-{[(4-cyano-3-methoxyphenyl)carbamothioyl]amino}phenyl)ethyl]carbamate
-
(2S)-1-cyanobutan-2-yl [(1R)-1-{3-[N''-cyano-N'-(4-cyano-3,5-dimethoxyphenyl)carbamimidamido]phenyl}ethyl]carbamate
-
(2S)-1-cyanobutan-2-yl [(1R)-1-{3-[N'-(3,4,5-trimethoxyphenyl)carbamimidamido]phenyl}ethyl]carbamate
-
(2S)-1-cyanobutan-2-yl [(1R)-1-{3-[N'-(4-cyano-3,5-dimethoxyphenyl)carbamimidamido]phenyl}ethyl]carbamate
-
(2S)-2-(2,3-dichloroanilino)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
(2S)-2-(2,3-dichlorophenoxy)-N-[2-(2-hydroxyphenyl)-1,3-benzoxazol-5-yl]propanamide
-
(2S)-2-(2,3-dichlorophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
(2S)-2-(2,3-dichlorophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-6-yl]propanamide
-
(2S)-2-(2,3-dichlorophenoxy)-N-[2-[4-(N'-hydroxycarbamimidoyl)phenyl]-1,3-benzoxazol-5-yl]propanamide
-
(2S)-2-(2,3-dimethoxyphenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
(2S)-2-(2-chloro-3-nitrophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
(2S)-2-(2-chlorophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
(2S)-2-[(1-naphthyl)amino]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
competitive versus NAD+
(2S)-2-[(3,4-dichlorophenyl)amino]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
competitive versus NAD+, displays excellent IMPDH inhibitory activity and moderate stability in mouse liver microsomes
(2S)-N-(4-iodophenyl)-2-(4-methoxyphenoxy)propanamide
7759844
(2S)-N-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-[4-(1-methyl-1H-imidazol-4-yl)phenoxy]propanamide
AT080
(3aR,4R,6S,7aR)-6-hydroxy-2,2-dimethyl-6-(propylcarbamoyl)hexahydro-2H-1,3-benzodioxol-4-yl (4E)-6-[4-(acetyloxy)-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
-
(3aR,4R,7S,8aR)-7-hydroxy-2,2-dimethyltetrahydro-2H-4,7-methano[1,3]dioxolo[4,5-c]oxepin-6(4H)-one
-
(3aR,5R,7R,7aS)-5,7-dihydroxy-2,2-dimethyl-N-propylhexahydro-2H-1,3-benzodioxole-5-carboxamide
-
(3S)-oxolan-3-yl {[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate
(3S,4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3,4-dimethylhex-4-enoic acid
-
(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)acetaldehyde
-
(4E)-6-(4,6-dihydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
derivative of mycophenolic acid. IC50 value for K562 cells proliferation 8.2 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 8.2 microM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-(1H-1,2,4-triazol-5-yl)hex-4-enamide
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[(2R)-2-phenylpropyl]hex-4-enamide
73.94% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[(2S)-2-phenylpropyl]hex-4-enamide
59.15% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[2-(2-methylphenyl)ethyl]hex-4-enamide
84% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[2-(4-methylphenyl)ethyl]hex-4-enamide
73.42% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[2-(pyridin-2-yl)ethyl]hex-4-enamide
59.38% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[2-(pyridin-4-yl)ethyl]hex-4-enamide
57.38% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[3-(morpholin-4-yl)propyl]hex-4-enamide
36.05% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[4-(trifluoromethyl)phenyl]hex-4-enamide
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-{[(1-nitro-4a,9a-dihydroacridin-9-yl)amino]methyl}hex-4-enamide
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-{[(4-nitro-9-oxo-4a,9,9a,10-tetrahydroacridin-1-yl)amino]methyl}hex-4-enamide
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enal
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-N-(3-methoxyphenyl)-4-methylhex-4-enamide
30.82% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-N-(4-methoxyphenyl)-4-methylhex-4-enamide
54.84% inhibition at 0.01 mM
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-N-[2-(4-methoxyphenyl)ethyl]-4-methylhex-4-enamide
96.13% inhibition at 0.01 mM
(4E)-6-[4-(acetyloxy)-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoic acid
derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.59 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.59 microM
(4E)-N-(2,3-dichlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-(3,4-dichlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-(4-chloro-3-methoxyphenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-(4-chlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-(4-chlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-N,4-dimethylhex-4-enamide
(4E)-N-(4-cyanophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-(4-fluorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-[(4-butylphenyl)methyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
93.62% inhibition at 0.01 mM
(4E)-N-[2-(2-chlorophenyl)ethyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
72.04% inhibition at 0.01 mM
(4E)-N-[2-(2H-1,3-benzodioxol-5-yl)ethyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
87.09% inhibition at 0.01 mM
(4E)-N-[2-(4-chlorophenyl)ethyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
81.36% inhibition at 0.01 mM
(4E)-N-[2-(furan-2-yl)ethyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
67.18% inhibition at 0.01 mM
(4E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4,6-dimethoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(4E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
(5E)-N-hydroxy-7-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-methylhept-5-enamide
-
comparison with inhibition of histone deacetylase and K562 cell proliferation
(5S)-7-amino-5-(4-chlorophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
F2K
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1,3,4-thiadiazol-2-yl)hex-4-enamide
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-1,2,4-triazol-5-yl)hex-4-enamide
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-tetrazol-5-yl)hex-4-enamide
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(4H-1,2,4-triazol-4-yl)hex-4-enamide
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(pyridin-2-yl)hex-4-enamide
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(thiazol-2-yl)hex-4-enamide
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioic S-acid
(E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enamide
(E)-N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-1-(thiophen-2-yl)methanimine
-
(R,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
(S)-2-(2,3-dichlorophenoxy)-N-(2-(2-methoxypyridin-4-yl)benzo-[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(2-oxo-1,2-dihydropyridin-4-yl)benzo[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(3-hydroxyphenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)benzo-[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)benzo[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-(hydrazinecarbonyl)phenyl)-benzo[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-(trifluoromethoxy)phenyl)-benzo[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-fluorophenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-hydroxyphenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]-oxazol-5-yl)propanethioamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-methoxyphenyl)imidazo-[1,2-a]pyridin-6-yl)propanamide
-
(S)-2-(2,3-dichlorophenoxy)-N-(2-(6-methoxypyridin-3-yl)benzo-[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-difluorophenoxy)-N-(2-(4-fluorophenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-difluorophenoxy)-N-(2-(4-hydroxyphenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-difluorophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2,3-difluorophenoxy)-N-(2-(6-methoxypyridin-3-yl)benzo-[d]oxazol-5-yl)propanamide
-
(S)-2-(2,3-difluorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)propanamide
-
(S)-2-(2-(aminomethyl)phenoxy)-N-(2-(4-methoxyphenyl)benzo-[d]oxazol-5-yl)propanamide
-
(S)-2-(2-(benzyloxy)phenoxy)-N-(2-(4-cyanophenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2-cyano-3-fluorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2-cyanophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]-oxazol-5-yl)propanamide
-
(S)-2-(2-cyanophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)-propanamide
-
(S)-2-(3-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]-oxazol-2-yl)phenoxy)acetic acid
-
(S)-2-(4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]-oxazol-2-yl)phenoxy)acetic acid
-
(S)-4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)-N-hydroxybenzamide
-
(S)-4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)benzamide
-
(S)-4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)benzoic acid
-
(S)-4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)pyridine-1-oxide
-
(S)-N-(2-(2,3-dichlorophenoxy)propyl)-2-(4-methoxyphenyl)-benzo[d]oxazol-5-amine
-
(S)-N-(2-(4-(1H-tetrazol-5-yl)phenyl)benzo[d]oxazol-5-yl)-2-(2,3-dichlorophenoxy)propanamide
-
(S)-N-(2-(4-(aminomethyl)phenyl)benzo[d]oxazol-5-yl)-2-(2,3-dichlorophenoxy)propanamide
-
(S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-((1-hydroxy-1,3-dihydrobenzo-[c][1,2]oxaborol-7-yl)oxy)propanamide
-
(S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-((2,3-dichlorophenyl)amino)propanamide
-
(S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3,4-trifluorophenoxy)propanamide
-
(S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-dichlorophenoxy)propanamide
-
(S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-difluorophenoxy)propanamide
-
(S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-(2-hydroxyphenoxy)propanamide
-
(S,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
([[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]oxy]methyl)phosphonic acid
-
isozyme IMPDH II IC50: 246 nM
([[(2E)-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]oxy]methyl)phosphonic acid
-
isozyme IMPDH II IC50: 23 nM
({hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl}methyl)phosphonic acid
-
1,4-dimethyl-6-nitro-2H-cyclopenta[d]pyridazine
-
1-(2,2-dimethylpropanoyl)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-1'H-spiro[pyrrolidine-3,2'-quinazolin]-4'(3'H)-one
-
IC50: 0.094 mM, isozyme IMPDH II
1-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)-3-quinolin-7-ylurea
displays high potency against Cryptosporidium parvum IMPDH, more than 1000fold selectivity versus human IMPDH type 2 and good stability in mouse liver microsomes
1-(3-methylphenyl)-3-[4-(1,3-oxazol-5-yl)phenyl]urea
-
isozyme IMPDH II IC50: 640 nM
1-(4-bromophenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]ethan-1-one
-
1-(4-chloro-5-nitrocyclohexa-1,5-dien-1-yl)-3-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
displays high potency against Cryptosporidium parvum IMPDH, more than 1000fold selectivity versus human IMPDH type 2 and good stability in mouse liver microsomes
1-(benzyloxy)-3-(3-pyridin-4-yl-1H-indol-6-yl)urea
-
1-methyl-6-[(5-phenyl-1,3-oxazol-2-yl)amino]-1H-indole-3-carbonitrile
-
1-phenylsulfonylindol-3-yl boronic acid
-
-
1-tert-butyl 5-methyl (3R,5R)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate
-
IC50: 35 nM, isozyme IMPDH II
1-tert-butyl 5-methyl (3R,5S)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate
-
IC50: 948 nM, isozyme IMPDH II
1-tert-butyl 5-methyl (3S,5R)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate
-
IC50: 35 nM, isozyme IMPDH II
1-tert-butyl 5-methyl (3S,5S)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1,5-dicarboxylate
-
26% inhibition at 10 micromol, isozyme IMPDH II
1-[(3,4-dichlorophenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
1-[(3,4-dichlorophenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
1-[(3-chlorophenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
1-[(3-chlorophenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
1-[(3-methoxyphenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
1-[(3-methoxyphenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
1-[(4-methoxyphenyl)methyl]-5-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
52.4% inhibition at 0.05 mM
1-[2-(cyclododecyloxy)-2-oxoethyl]-1-methylpiperidin-1-ium
-
i.e. 5F02, about 40% inhibition at 4 mM, less than 20% inhibition at 1 and 8 mM
1-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]-3-quinolin-7-ylurea
displays high potency against Cryptosporidium parvum IMPDH, more than 1000fold selectivity versus human IMPDH type 2 and good stability in mouse liver microsomes
1-[3,4-bis(benzyloxy)-5-oxo-2,5-dihydrofuran-2-yl]ethane-1,2-diyl diacetate
-
1-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]-3-(3-methylphenyl)urea
-
isozyme IMPDH II IC50: 43 nM
1-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-3-(3-methylphenyl)urea
-
isozyme IMPDH II IC50: 19 nM
1-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]-3-(3-methylphenyl)urea
-
isozyme IMPDH II IC50: 500 nM
1-{5-O-[hydroxy({hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl}methyl)phosphoryl]-beta-D-ribofuranosyl}-1H-benzimidazol-4-amine
-
14,16-dihydroxy-3,8-dimethyl-3,4,5,6,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione
inhibition of leukemia K562 cells proliferation, IC50 of 71.3 microM
1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate
2'-deoxy-ATP
-
18% inhibition at 0.5 mM
2'-deoxy-GDP
-
12% inhibition at 0.5 mM
2'-deoxy-GTP
-
21% inhibition at 0.5 mM
2'-methylthiazole-4-carboxamide adenine dinucleotide
-
noncompetitive inhibition, less cytotoxic against K562 tumor cells
2,2,2-trichloroethyl (1-oxo-1,3-dihydro-2-benzofuran-5-yl)carbamate
-
2-(1,3-oxazol-5-yl)-5-[(5-phenyl-1,3-oxazol-2-yl)amino]phenol
-
isozyme IMPDH II IC50: 0.0016 mM
2-(1-benzothiophen-3-yl)-6-methoxy-5-(1,3-oxazol-2-yl)-1H-indole-3-carbaldehyde
-
2-(1-benzothiophen-3-yl)-6-methoxy-5-(1,3-oxazol-5-yl)-1H-indole-3-carbaldehyde
-
2-(1-naphthalenyloxy)-N-[(2-(4-pyridinyl)-5-benzoxazolyl)]-(2S)-propanamide
2-(2,4-dichlorophenoxy)-N-[2-(pyridin-2-yl)-1,3-benzoxazol-5-yl]propanamide
-
2-(2-chlorophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)-N-(6,7,8,9-tetrahydrodibenzo[b,d]furan-2-yl)acetamide
D67
2-(4-benzoylphenyl)-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)propanamide
95.2% inhibition at 0.05 mM
2-(4-fluoronaphthalen-1-yl)-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
99.9% inhibition at 0.05 mM
2-(4-methoxyphenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
2-(dimethylamino)-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 200 nM
2-(methyl{2-[(2lambda~5~-triaza-1,2-dien-2-yl)acetyl]phenyl}amino)-2-oxoethyl acetate
-
2-([2-[2-(furan-2-yl)phenyl]-4-oxo-4H-1-benzopyran-3-yl]oxy)-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
2-amino-oxazole-cyanoindoles
-
-
-
2-anilino-5-fluorobenzene-1,4-dicarboxylic acid
-
2-benzyl-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 180 nM
2-beta-D-ribofuranosylthiazole-4-carboxamide
-
NSC 286193, RTC
2-beta-D-ribofuranosylthiazole-4-carboxamide 5'-phosphate
-
RTC monophosphate
2-chloro-5-[[(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)carbamoyl]amino]benzamide
P32
2-chloro-5-[[(2-[3-[(1Z)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)carbamoyl]amino]-N,N-dimethylbenzamide
-
2-chloro-5-[[(2-[3-[(1Z)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)carbamoyl]amino]benzamide
-
2-chloro-N,N-diethyl-5-[[(2-[3-[(1Z)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)carbamoyl]amino]benzamide
-
2-chloro-N,N-dimethyl-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl[carbamoyl)amino]benzamide
P41
2-chloro-N,N-dimethyl-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]benzamide
2-chloro-N-methyl-5-[[[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]amino]carbonyl]aminobenzamide
2-cyano-1-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-3-phenylguanidine
-
isozyme IMPDH II IC50: 240 nM
2-ethyl-5'-O-[hydroxy({hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl}methyl)phosphoryl]adenosine
-
2-ethyl-9-[5-O-[hydroxy(2-[hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]ethyl)phosphoryl]-beta-L-ribofuranosyl]-9H-purin-6-amine
inhibition of leukemia K562 cells proliferation, IC50 of 4.0 microM; inhibition of leukemia K562 cells proliferation, IC50 of 4.0 microM
2-fluoro-9-oxo-4a,9,9a,10-tetrahydroacridine-3-carboxylic acid
-
2-furan-3-yl-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 32 nM
2-hydroxy-N-[2-(2-[[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methylacetamide
-
isozyme IMPDH II IC50: 41 nM
2-mercaptoethanol
-
inhibits above 2 mM
2-methoxy-1-methyl-4-nitrobenzene
-
2-methoxy-4-nitrobenzaldehyde
-
2-methyl-3-(pyrid-4-yl)indole
-
IC50: 343 nM
2-methylquinolin-8-yl 4-methylnaphthalene-1-sulfonate
-
ZINC58646829
2-oxo-4-(trifluoromethyl)-2H-1-benzopyran-7-yl 5-methylquinoline-8-sulfonate
-
ZINC46542062
2-phenoxy-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
2-tert-butyl-7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 0.01 mM
2-[(2-{2-[3-methoxy-4-(1,3-oxazol-5-yl)anilino]-1,3-oxazol-5-yl}phenyl)(methyl)amino]-2-oxoethyl acetate
-
2-[(3,4-dichlorophenyl)amino]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
racemic variant, competitive versus NAD+. Compound displays good antiparasitic activity in a Toxoplasma gondii strain that relies on Cryptosporidium parvum IMPDH, EC50 20 nM. No toxicity is observed against four mammalian cells lines
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
2-[2-(Z)-fluorovinyl]-inosine 5'-phosphate
-
is a time-dependent inactivator
2-[4-([1-[(2-fluorophenyl)methyl]-1H-1,2,3-triazol-5-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
71% inhibition at 0.05 mM
2-[4-([1-[(3,4-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
2-[4-([1-[(3-chlorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
2-[4-([1-[(3-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
2-[4-([1-[(3-methoxyphenyl)methyl]-1H-1,2,3-triazol-5-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
35% inhibition at 0.05 mM
2-[4-([1-[([1,1'-biphenyl]-4-yl)methyl]-1H-1,2,3-triazol-5-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
72.6% inhibition at 0.05 mM
2-[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]propan-2-amine
-
2-[methyl[2-(2-[[3-(1,3-oxazol-5-yl)-1H-indol-6-yl]amino]-1,3-oxazol-5-yl)phenyl]amino]-2-oxoethyl acetate
-
2-[[2-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
2-[[2-(3,4-dimethoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
2-[[2-(3,4-dimethoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(naphthalen-1-yl)acetamide
2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(naphthalen-1-yl)acetamide
2-[[2-(4-methylphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
2264A
inhibits lymphocyte proliferation; inhibits lymphocyte proliferation
2264B
inhibits lymphocyte proliferation; inhibits lymphocyte proliferation
3'-methylthiazole-4-carboxamide adenine dinucleotide
-
noncompetitive inhibition, less cytotoxic against K562 tumor cells
3'-[N''-cyano-N'-(4-cyano-3-methoxyphenyl)carbamimidamido][1,1'-biphenyl]-3-carboxylic acid
-
3,4-dihydro-3-methyl-4-oxo-N-(6,7,8,9-tetrahydro2-dibenzofuranyl)-1-phthalazineacetamide
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
3-(2-[[(4-chlorophenyl)carbamoyl]amino]propan-2-yl)-N-hydroxybenzene-1-carboximidamide
3-(2-{2-[3-methoxy-4-(1,3-oxazol-5-yl)anilino]-1,3-oxazol-5-yl}phenyl)-1-(morpholin-4-yl)butan-2-one
i.e. BMS-337197
3-(4-chlorophenyl)-4-(4-ethoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
3-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)propyl (4-chlorophenyl)carbamate
3-cyanoindole
-
inhibits isozyme IMPDH II at 0.03 mM
3-cyanoindole-based inhibitors
-
synthesis and initial structure–activity relationships of 3-cyanoindole-based inhibitors with isozyme IMPDH II, IC50: 33-420 nM, comparison to other inhibitor structural classes, overview
-
3-formyl-1-methylindole
-
-
3-hydroxy-N-methyl-N-[2-(2-[[3-methyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]propanamide
-
isozyme IMPDH II IC50: 100 nM
3-hydroxy-N-[2-(2-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methylpropanamide
-
isozyme IMPDH II IC50: 21 nM
3-methoxy-4-(1,3-oxazol-5-yl)aniline
-
3-methoxy-4-(oxazol-5-yl)aniline
-
-
3-phenyl quinolone derivatives
-
several, isozyme IMPDH II IC50: 5-160 nM, overview
-
3-{3-[N''-cyano-N'-(4-cyano-3-methoxyphenyl)carbamimidamido]phenyl}propanoic acid
-
4-(3-bromo-4-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
4-(4-acetamidophenyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
4-(4-acetamidophenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
4-(4-bromophenyl)-1H-imidazole
NMR744
4-(5-bromo-2-fluorophenyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
4-(5-bromo-2-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
4-acetyl-N-(3-chloro-4-fluorophenyl)-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide
4-isothiocyanato-1,2-dimethoxybenzene
-
4-isothiocyanato-2-methoxybenzonitrile
-
4-nitro-1-beta-D-ribofuranosyl-1H-benzimidazole
-
4-pyridylindole
-
IC50: 0.00115 mM
4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinolin-2(1H)-one
4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinoline 1-oxide
4-[(1R)-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4yl]ethoxy]quinoline-1-oxide
4-[(5-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl)methyl]benzonitrile
43.5% inhibition at 0.05 mM
4-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-6-phenyl-1,3,5-triazin-2-ol
-
5'-amino-5'-deoxyadenosine
-
5'-deoxy-5'-[(3-{[(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoyl]amino}-2-oxopropyl)amino]adenosine
-
5'-O-([1-[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]-1H-1,2,3-triazol-4-yl[methyl)adenosine
MAD1, uncompetitive inhibitor
5'-O-([1-[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]-1H-1,2,3-triazol-4-yl]methyl)adenosine
an uncompetitive inhibitor with a strong preference for the E-XMP reaction intermediate, enzyme binding structure analysis, overview
5'-O-({[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]sulfamoyl}methanesulfonyl)adenosine
-
5'-O-[hydroxy({hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl}methyl)phosphoryl]adenosine
-
5'-thio-IMP
-
competitive inhibitor
5,5'-dithiobis(2-nitrobenzoate)
-
-
5,6,7,8-tetrahydroquinoxalin-6-yl 8-methylquinoline-5-sulfonate
-
ZINC89780094
5-(2-methoxy-4-nitrophenyl)-1,3-oxazole
-
5-(4-isothiocyanato-2-methoxyphenyl)-1,3-oxazole
-
5-([[2-([1,1'-biphenyl]-3-yl)propan-2-yl]carbamoyl]amino)-2-chlorobenzamide
-
-
5-aminoisobenzofuran-1(3H)-one
-
5-bromoisoquinolin-6-amine
-
5-chloro-1,4-dimethyl-2H-cyclopenta[d]pyridazine-6-carbonitrile
-
6,6'-oxydi(1,4-dihydroquinoxaline-2,3-dione)
binds in the nicotinamide subsite and does not interact with ADP
6-((E)-4-(((1-(50-deoxy-adenosin-50-yl)-1H-1,2,3-triazol-4-yl)-methyl)amino)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one
-
6-((E)-4-(4-(adenosin-50-yl)methyl-1H-1,2,3-triazol-1-yl)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one
6-(4-ethylpiperazin-1-yl)pyridine-3-carbonitrile
-
6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate
6-chloroinosine 5'-phosphate
6-Chloropurine
irreversible inhibitor
6-Chloropurine ribonucleoside 5'-phosphate
6-mercaptopurine ribonucleotide
-
-
6-thioguanosine
-
expression of isoform IMPDH2 increases modestly in response to 6-thioguanosine exposure. However, the basal enzyme activity decreases when the cells are exposed to a proliferation-blocking 6-thioguanosine concentration
6-thioinosine 5'-phosphate
6-{(2E)-4-[4-({[(2S,5R)-5-(6-amino-7,8-dihydro-9H-purin-9-yl)oxolan-2-yl]methoxy}methyl)-1H-1,2,3-triazol-1-yl]-3-methylbut-2-en-1-yl}-7-hydroxy-5-methoxy-4-methyl-2-benzofuran-1(3H)-one
-
7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-1'H-spiro[cyclopentane-1,2'-quinazolin]-4'(3'H)-one
-
IC50: 328 nM, isozyme IMPDH II
7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-1-(piperidin-1-ylcarbonyl)-1'H-spiro[pyrrolidine-3,2'-quinazolin]-4'(3'H)-one
-
IC50: 0.068 mM, isozyme IMPDH II
7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-2,3,5,6-tetrahydro-1'H-spiro[pyran-4,2'-quinazolin]-4'(3'H)-one
-
IC50: 526 nM, isozyme IMPDH II
7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-N-phenyl-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.393 mM, isozyme IMPDH II
7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4,6-dihydro-1'H-spiro[cyclopenta[b]thiophene-5,2'-quinazolin]-4'(3'H)-one
-
IC50: 96 nM, isozyme IMPDH II
7'-methoxy-3'-methyl-N,N-bis(1-methylethyl)-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.071 mM, isozyme IMPDH II
7'-methoxy-N,3'-dimethyl-6'-(1,3-oxazol-5-yl)-4'-oxo-N-phenyl-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.064 mM, isozyme IMPDH II
7-amino-5-(4-chlorophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-5-(5-nitrothiophen-2-yl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
7-hydroxy-5-methoxy-4-methyl-6-(3-methylbut-2-en-1-yl)-2-benzofuran-1(3H)-one
-
isozyme IMPDH II IC50: 254 nM
7-hydroxy-5-methoxy-4-methyl-6-[(2E)-3-methyl-4-(2lambda~5~-triaza-1,2-dien-2-yl)but-2-en-1-yl]-2-benzofuran-1(3H)-one
-
7-hydroxy-5-methoxy-4-methyl-6-{(2E)-3-methyl-6-[(2R)-oxiran-2-yl]-6-oxohex-2-en-1-yl}-2-benzofuran-1(3H)-one
-
7-hydroxy-5-methoxy-4-methyl-6-{(2E)-3-methyl-6-[(2S)-oxiran-2-yl]-6-oxohex-2-en-1-yl}-2-benzofuran-1(3H)-one
-
7-hydroxy-5-methoxy-6-[(2E)-4-methoxy-3-methylbut-2-en-1-yl]-4-methyl-2-benzofuran-1(3H)-one
-
isozyme IMPDH II IC50: 273 nM
7-hydroxy-6-[(2E)-6-hydroxy-3-methylocta-2,7-dien-1-yl]-5-methoxy-4-methyl-2-benzofuran-1(3H)-one
-
7-methoxy-2,2,3-trimethyl-6-(1,3-oxazol-5-yl)-2,3-dihydroquinazolin-4(1H)-one
-
IC50: 192 nM, isozyme IMPDH II
7-methoxy-2,2-dimethyl-6-(1,3-oxazol-5-yl)-3-(2-pyridin-4-ylethyl)-2,3-dihydroquinazolin-4(1H)-one
-
IC50: 300 nM, isozyme IMPDH II
7-methoxy-2,3-dimethyl-6-(1,3-oxazol-5-yl)-2-[(E)-2-phenylethenyl]-2,3-dihydroquinazolin-4(1H)-one
-
IC50: 49 nM, isozyme IMPDH II
7-methoxy-2-(3-methylphenyl)-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
7-methoxy-2-(methylamino)-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 220 nM
7-methoxy-2-methyl-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 110 nM
7-methoxy-3-methyl-6-(1,3-oxazol-5-yl)-2-phenylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 65 nM
7-methoxy-3-methyl-6-(1,3-oxazol-5-yl)quinazoline-2,4(1H,3H)-dione
-
IC50: 104 nM, isozyme IMPDH II
7-methoxy-6-(1,3-oxazol-2-yl)-2-phenylquinolin-4(1H)-one
-
7-methoxy-6-(1,3-oxazol-4-yl)-2-phenylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 210 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-(1,3-thiazol-4-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 34 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-phenoxyquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 8 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-phenylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 8 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-pyridin-2-ylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 43 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-pyridin-3-ylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 70 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-pyridin-4-ylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 46 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-thiophen-2-ylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 63 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-thiophen-3-ylquinolin-4(1H)-one
-
isozyme IMPDH II IC50: 9 nM
7-methoxy-6-(1,3-oxazol-5-yl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one
-
IC50: 303 nM
7-methoxy-6-(1,3-oxazol-5-yl)-3-(2-pyridin-4-ylethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one
-
7-methoxy-6-(1,3-oxazol-5-yl)-3-[2-(pyridin-4-yl)ethyl]-2-sulfanylidene-2,3-dihydroquinazolin-4(1H)-one
-
7-methoxy-6-(1,3-oxazol-5-yl)quinolin-4(1H)-one
-
isozyme IMPDH II IC50: 300 nM
8-methoxy-8-oxooctanoic acid
-
9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-2-ethyl-9H-purin-6-amine
-
9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-2-ethynyl-9H-purin-6-amine
-
9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-2-phenyl-9H-purin-6-amine
-
9-(5-deoxy-5-([(([2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]sulfonyl)methyl)sulfonyl]amino)-b-L-ribofuranosyl)-9H-purin-6-amine
-
9-(5-O-[hydroxy[([hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]oxy)methyl]phosphoryl]-beta-L-ribofuranosyl)-9H-purin-6-amine
allopurinol ribonucleotide
-
-
APAD+
substrate inhibition, uncompetitive substrate inhibition versus IMP
AVN944
induces caspase-independent apoptosis in multiple myeloma cell lines and displays antiproliferative activity against both androgen-dependent and androgen-independent prostate cancer cell lines; induces caspase-independent apoptosis in multiple myeloma cell lines and displays antiproliferative activity against both androgen-dependent and androgen-independent prostate cancer cell lines
beta-difluoromethylene-tiazofurin
-
beta-methylene thiazole 4-carboxamide adenine dinucleotide
beta-methylene-TAD
-
noncompetitive inhibition
beta-methylene-thiazole-4-carboxamide adenine dinucleotide
-
i.e. beta-Me-TAD, enzyme binding structure analysis, the enzyme active site loop is ordered in this complex, and the catalytic Cys319 is 3.6 A from IMP, in the same plane as the hypoxanthine ring, the active site loop forms hydrogen bonds to the carboxamide of beta-Me-TAD, overview
beta-methylene-thiazole-4-carboxyamide-adenine dinucleotide
-
-
beta-methylene-tiazofurin
-
C2-mycophenolic adenine dinucleotide
C4-mycophenolic adenine dinucleotide
-
methylenephosphophosphonate analogue of mycophenolic adenine dinucleotide
CH2-SAD
i.e. 4-carboxamido-2-beta-D-ribofuranosylselenazolyl adenosine methylenediphosphonic acid, an adenine dinucleotide analogue nonhydrolyzable beta-methylene derivative
CH2-TAD
i.e. 4-carboxamido-2-beta-D-ribofuranosylthiazolyl adenosine methylenediphosphonic acid, an adenine dinucleotide analogue nonhydrolyzable beta-methylene derivative
chlorogenic acid
0.1 mM, 30% inhibition
CMP
-
25% inhibition at 0.6 mM
cyclohexyl[4-(isoquinoline-5-sulfonyl)piperazin-1-yl]methanone
dimethyl (2-[[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]amino]ethyl)phosphonate
-
isozyme IMPDH II IC50: above 0.001 mM
dimethyl 1-{(2Z)-2-[3,4-bis(benzyloxy)-5-oxofuran-2(5H)-ylidene]ethyl}-4,5-dihydro-1H-imidazole-4,5-dicarboxylate
-
dimethyl 2-amino-5-fluorobenzene-1,4-dicarboxylate
-
dimethyl 2-fluorobenzene-1,4-dicarboxylate
-
dimethyl 4,5-dihydro-1H-imidazole-4,5-dicarboxylate
-
dimethyl [(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]phosphonate
-
isozyme IMPDH II IC50: 289 nM
dithioerythrol
-
inhibits above 1 mM
ellagic acid
0.1 mM, 27% inhibition
epigallocatechin gallate
0.1 mM, 47% inhibition
ethyl (2E)-3-[3-methoxy-4-(1,3-oxazol-5-yl)anilino]-3-phenylprop-2-enoate
-
ethyl (2E)-3-[4-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]prop-2-enoate
-
ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoyl carbonate
-
ethyl (S)-2-(3-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo-[d]oxazol-2-yl)phenoxy)acetate
-
ethyl (S)-2-(4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo-[d]oxazol-2-yl)phenoxy)acetate
-
ethyl 7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxylate
-
IC50: 0.08 mM, isozyme IMPDH II
ethyl 9-oxo-9,10-dihydroacridine-1-carboxylate
-
Fe3+
-
11% inhibition at 1 nM
HgCl2
-
complete inactivation at 0.5 mM
imidazo[4,5-e][1,4]diazapine
Inosine
-
very weak, non-competitive
Inosine 5'-methylphosphonate
-
very weak, non-competitive
Inosine 5'-phosphite
-
very weak, non-competitive
Inosine 5'-phosphofluoridate
-
very weak, non-competitive
merimepodib
has immunosuppressive activity; has immunosuppressive activity
methyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.73 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 0.73 microM
methyl (S)-4-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo-[d]oxazol-2-yl)benzoate
-
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
methyl methanethiosulfonate
-
-
methyl N-[(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoyl]alaninate
-
mizobirine 5'-monophosphate
-
mizoribine 5'-monophosphate
-
mycophenolic 2-ethyladenosin-5'-yl-difluoromethylenebis(phosphonate)
potent, sub-micromolar inhibitor of leukemia K562 cells proliferation, IC50 of 0.45 microM; potent, sub-micromolar inhibitor of leukemia K562 cells proliferation, IC50 of 0.45 microM
mycophenolic 2-ethyladenosin-5'-yl-methylenebis(phosphonate)
inhibition of leukemia K562 cells proliferation, IC50 of 1.0 microM; inhibition of leukemia K562 cells proliferation, IC50 of 1.0 microM
mycophenolic acid glucuronide
-
80% inhibition at 0.2 mM, human plasma or serum reduces the inhibition
mycophenolic acid sodium
-
mycophenolic acid-acyl-glucuronide
mycophenolic adenine dinucleotide
-
-
mycophenolic hydroxamic acid
-
comparison with inhibition of histone deacetylase and K562 cell proliferation
N''-cyano-N-(3'-cyano[1,1'-biphenyl]-3-yl)-N'-(4-cyano-3-methoxyphenyl)guanidine
-
N''-cyano-N-(4'-cyano[1,1'-biphenyl]-3-yl)-N'-(4-cyano-3-methoxyphenyl)guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-(2'-fluoro[1,1'-biphenyl]-3-yl)guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-(3'-fluoro[1,1'-biphenyl]-3-yl)guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-(4'-fluoro[1,1'-biphenyl]-3-yl)guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-[3-(1-hydroxyethenyl)phenyl]guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-[3-(2-hydroxyprop-2-en-1-yl)phenyl]guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-[3-(2-methyl-2H-tetrazol-5-yl)phenyl]guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-{3-[(1-methyl-1H-tetrazol-5-yl)methyl]phenyl}guanidine
-
N''-cyano-N-(4-cyano-3-methoxyphenyl)-N'-{3-[(2-methyl-2H-tetrazol-5-yl)methyl]phenyl}guanidine
-
N,7'-dimethoxy-N,3'-dimethyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.079 mM, isozyme IMPDH II
N,N-diethyl-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.045 mM, isozyme IMPDH II
N-(1,4-dinitroacridin-9-yl)methanediamine
-
N-(1-nitroacridin-9-yl)methanediamine
-
N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-([4-oxo-2-[2-(thiophen-2-yl)phenyl]-4H-1-benzopyran-3-yl]oxy)acetamide
N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-[[4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-3-yl]oxy]acetamide
N-(2,3-dichlorophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide
poor inhibition of human IMPDH2
N-(2,4-difluorophenyl)-7'-methoxy-N,3'-dimethyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.051 mM, isozyme IMPDH II
N-(2-[3-[(1E)-N-(2-aminoethoxy)ethanimidoyl]phenyl[propan-2-yl)-N'-(4-chloro-3-nitrophenyl)urea
-
P131
N-(2-{2-[3-methoxy-4-(1,3-oxazol-5-yl)anilino]-1,3-oxazol-5-yl}phenyl)-N-methyl-2-(morpholin-4-yl)acetamide
-
N-(2-{3-[(1E)-N-(2-aminoethoxy)ethanimidoyl]phenyl}propan-2-yl)-N'-(4-chloro-3-nitrophenyl)urea
N-(2H-indazol-6-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide
N-(4-bromophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide
N-(4-bromophenyl)-2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]acetamide
N-(4-bromophenyl)-2-[[2-(4-methylphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]acetamide
N-(4-bromophenyl)-N'-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
P68
N-(4-bromophenyl)-N'-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]urea
P12
N-(4-bromophenyl)-N-[(1-methylethenyl)phenyl]ethyl urea
N-(4-bromophenyl)-N-[1-[3-[1-(hydroxyimino)ethyl]phenyl]-1-methylethyl] urea
N-(4-chloro-3-methoxyphenyl)-2-(4-oxo[1]benzopyrano[4,3-c]pyrazol-1(4H)-yl)acetamide
N-(4-chlorophenyl)-2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
N-(4-chlorophenyl)-2-phenoxypropanamide
N-(4-chlorophenyl)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)butanamide
N-(4-fluorophenyl)-4-[(2H-indazol-6-yl)sulfamoyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide
-
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
N-(4-methoxyphenyl)-2-(naphthalen-1-yl)acetamide
N-(4-methoxyphenyl)-2-naphthalen-1-ylacetamide
binds in the nicotinamide subsite and does not interact with ADP
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
N-(5-phenyl-1,3-oxazol-2-yl)isoquinolin-6-amine
-
N-(naphthalen-1-yl)-2-[(4-oxo-2-phenyl-4H-1-benzopyran-3-yl)oxy]acetamide
N-(naphthalen-1-yl)-2-[[4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-3-yl]oxy]acetamide
N-(naphthalen-2-yl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide
poor inhibition of human IMPDH2
N-(naphthalen-2-yl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide
N-ethyl-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxamide
-
IC50: 0.119 mM, isozyme IMPDH II
N-ethylmaleimide
-
100% inhibition at 1 mM
N-hydroxy-N'-[3-methoxy-4-(1,3-oxazol-2-yl)phenyl]octanediamide
-
comparison with inhibition of histone deacetylase and K562 cell proliferation
N-methyl-N'-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)urea
-
N-methyl-N'-[4-(1,3-oxazol-5-yl)phenyl]-6-phenyl-1,3,5-triazine-2,4-diamine
-
isozyme IMPDH II IC50: 0.005 mM
N-methyl-N'-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]-6-phenyl-1,3,5-triazine-2,4-diamine
-
isozyme IMPDH II IC50: 0.005 mM
N-methyl-N-[2-(2-[[3-methyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-morpholin-4-ylpropanamide
-
isozyme IMPDH II IC50: 45 nM
N-naphthalen-2-yl-N'-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]urea
-
-
N-tert-butyl-N'-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]ethanediamide
-
isozyme IMPDH II IC50: 55 nM
N-tert-butyl-N'-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]ethanediamide
-
isozyme IMPDH II IC50: 10 nM
N-tert-butyl-N'-[4-(1,3-oxazol-5-yl)phenyl]ethanediamide
-
isozyme IMPDH II IC50: 0.005 mM
N-tert-butyl-N'-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]ethanediamide
-
isozyme IMPDH II IC50: 0.005 mM
N-[(1R)-1-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]ethyl[-N'-phenylurea
G36
N-[(4-fluorophenyl)(1-methyl-1H-imidazol-2-yl)methyl]-2-methyl-3-(1,2,4-thiadiazol-5-yl)-1H-indole-6-carboxamide
-
N-[(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoyl]alanine
-
N-[(Z)-(pyridin-3-ylimino)methyl]-2,3-dihydro-1,4-benzodioxine-2-carboxamide
-
N-[1-[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]-1-methylethyl]-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide
-
N-[2-(2-[[3-(chloromethyl)-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide
-
isozyme IMPDH II IC50: 47 nM
N-[2-(2-[[3-bromo-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-hydroxy-N-methylpropanamide
-
isozyme IMPDH II IC50: 28 nM
N-[2-(2-[[3-bromo-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide
-
isozyme IMPDH II IC50: 21 nM
N-[2-(2-[[3-chloro-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-hydroxy-N-methylpropanamide
-
isozyme IMPDH II IC50: 48 nM
N-[2-(2-[[3-ethyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-3-hydroxy-N-methylpropanamide
-
isozyme IMPDH II IC50: 310 nM
N-[2-(2-[[3-ethyl-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide
-
isozyme IMPDH II IC50: 21 nM
N-[2-(2-[[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-2-morpholin-4-ylacetamide
-
isozyme IMPDH II IC50: 91 nM
N-[2-(2-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-2-morpholin-4-ylacetamide
-
N-[2-(2-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]amino]-1,3-oxazol-5-yl)phenyl]-N-methyl-3-morpholin-4-ylpropanamide
-
isozyme IMPDH II IC50: 16 nM
N-[2-(4-cyanophenyl)-1,3-benzoxazol-5-yl]-N2-(2,3-dichlorophenyl)-L-alaninamide
-
N-[2-(4-cyanophenyl)-1,3-benzoxazol-5-yl]-N2-(2,3-difluorophenyl)-L-alaninamide
-
N-[2-(hydroxymethyl)cyclopentyl]-N'-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]propanediamide
-
N-[2-chloro-3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[2-chloro-5-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.0016 mM
N-[2-chloro-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenyl]-beta-D-xylofuranosylamine
N-[2-chloro-5-[([2-[3-(propan-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenyl]-?-D-ribofuranosylamine
P176
N-[2-fluoro-5-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[3-bromo-4-(1,3-oxazol-5-yl)phenyl]-N'-tert-butylethanediamide
-
isozyme IMPDH II IC50: 50 nM
N-[3-chloro-4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 88 nM
N-[3-chloro-4-(1,3-oxazol-5-yl)phenyl]-N'-methyl-6-phenyl-1,3,5-triazine-2,4-diamine
-
isozyme IMPDH II IC50: 340 nM
N-[3-ethoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.010 mM
N-[3-methoxy-4-(1,3-oxazol-2-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 190 nM
N-[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 57 nM
N-[3-methoxy-4-(1,3-oxazol-4-yl)phenyl]-N'-methyl-6-phenyl-1,3,5-triazine-2,4-diamine
-
isozyme IMPDH II IC50: 0.0016 mM
N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 20 nM
N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-N'-methyl-6-phenyl-1,3,5-triazine-2,4-diamine
-
isozyme IMPDH II IC50: 76 nM
N-[3-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 410 nM
N-[3-methoxy-4-(2-methyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.002 mM
N-[3-methoxy-4-(4-methyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[3-methyl-4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[4-(1,3-oxazol-4-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[4-(1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[4-(1-benzyl-2,4,6-trioxo-2,3,4,5,6,11-hexahydro-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidin-5-yl)phenyl]acetamide
N-[4-(2,4-dimethyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.002 mM
N-[4-(4-methyl-1,3-oxazol-5-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine
-
isozyme IMPDH II IC50: 0.005 mM
N-[4-chloro-3-(alpha-D-ribofuranosyloxy)phenyl]-N'-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]urea
N-[4-chloro-3-(morpholine-4-carbonyl)phenyl]-N'-(2-[3-[(1Z)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
noncompetitive with respect to NAD+, displays submicromolar activity in a Toxoplasma gondii model of Cryptosporidium parvum infection and displays good stability in mouse liver microsome. No antiparasitic activity is observed in mouse with once per day oral dosing of 250 mg/kg for 7 days
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(1R,2S)-2-[(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]-1-methylcyclopropyl]propanamide
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(1S,2R)-2-[(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]-1-methylcyclopropyl]propanamide
N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhexanamide
N-[4-chloro-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-N'-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
N-{2-[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]propan-2-yl}-2-fluoro-9-oxo-4a,9,9a,10-tetrahydroacridine-3-carboxamide
-
N-{2-[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]propan-2-yl}-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide
-
N1-methyl-N~2~-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethanediamide
-
N2-(2,3-dichlorophenyl)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]-L-alaninamide
NADPH
-
50% inhibition at 0.14 mM
NH4+
-
25% inhibition at 2.12 M
nicotinic acid
-
inhibitory analog of NAD+, non-competitive with respect to IMP and K+
N~1~-hydroxy-N~8~-phenyloctanediamide
-
N~1~-hydroxy-N~8~-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]octanediamide
-
N~2~-(2,3-dichlorophenyl)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]alaninamide
-
olaparib
-
about 70% inhibition at 8 mM
oxolan-3-yl {[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate
-
p-hydroxymercuribenzoate
-
97% inactivation at 1 mM
P1-(7-hydroxy-6-(ethyl-2-yl)-5-methoxy-4-methylphthalan-1-one)methylenephospho-P2-(adenosin-5'-yl)phosphonate
-
-
P1-(adenosine-5'-yl)methylenephospho-P2-(7-hydroxy-6-(ethyl-2-yl)-5-methoxy-4-methylphthalan-1-one)phosphonate
-
-
P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate
P1-(tiazofurin-5'-yl)-P2-(2-aminoadenosin-5'-yl) diphosphate
-
comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
P1-(tiazofurin-5'-yl)-P2-(2-ethyladenosin-5'-yl) diphosphate
-
comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
P1-(tiazofurin-5'-yl)-P2-(2-ethynyladenosin-5'-yl) diphosphate
-
comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
P1-(tiazofurin-5'-yl)-P2-(2-iodoadenosin-5'-yl) diphosphate
-
comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
P1-(tiazofurin-5'-yl)-P2-(2-phenyladenosin-5'-yl) diphosphate
-
comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
P1-(tiazofurin-5'-yl)-P2-(adenosin-5'-yl) diphosphate
-
comparison with inhibition of alcohol dehydrogenase, malate dehydrogenase, lactate dehydrogenase and K562 cell proliferation
P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(2-ethyladenosin-5'-yl)methylenebis(phosphonate)
P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(2-phenyladenosin-5'-yl)methylenebis(phosphonate)
-
P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(adenosin-5'-yl)methylenebis(phosphonate)
-
phenyl N'-cyano-N-(3-[cyano[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamimidamido]benzyl)imidocarbamate
-
phosphate
-
mixed inhibition kinetics
prop-2-yn-1-yl (S)-2-(4-(5-(2-(2,3-dichlorophenoxy)-propanamido)benzo[d]oxa-zol-2-yl)phenoxy)acetate
-
propan-2-yl {3-[N''-cyano-N'-(4-cyano-3-methoxyphenyl)carbamimidamido]phenoxy}acetate
-
quinazolinedione derivatives
-
several derivatives, synthesis and inhibitory values, overview
-
quinazolinethione derivatives
-
several derivatives, synthesis and inhibitory values, overview
-
ribavirin 5'-monophosphate
ribose 5-phosphate
-
non-competitive
S-(prop-1-en-2-yl) (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioate
S-[(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-en-1-yl] ethanethioate
-
SAD
i.e. selenazole-4-carboxamido adenine diphosphonic acid, an adenine dinucleotide analogue
selenazole adenine dinucleotide
-
-
selenazole-4-carboxyamide-adenine dinucleotide
-
Sesquiterpene lactones
-
a class of anti-neoplastic drugs, overview
-
TAD
i.e. thiazole-4-carboxamide adenine dinucleotide, an adenine dinucleotide analogue
tert-butyl 7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1H,1'H-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxylate
-
IC50: 104 nM, isozyme IMPDH II
tert-butyl methyl (1S,4S)-7'-methoxy-3'-methyl-6'-(1,3-oxazol-5-yl)-4'-oxo-3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-quinazoline]-3,4-dicarboxylate
-
tetrasodium 6,6'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(E)-diazene-2,1-diyl]]bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
thiazofurin-5'-yl-2-ethyladenosin-5'-yl-difluromethylene bis(phosphonate)
inhibition of leukemia K562 cells proliferation, IC50 of 4.7 microM; inhibition of leukemia K562 cells proliferation, IC50 of 4.7 microM
thiazole-4-carboxamide 2-ethyladenine dinucleotide
-
thiazole-4-carboxamide adenine dinucleotide
TMP
-
25% inhibition at 0.6 mM
UMP
-
25% inhibition at 0.6 mM
Urea
-
inactive at 3 M but regains activity after dialysis
VCC234718
-
uncompetitive inhibition with respect to IMP and NAD+
Zn2+
-
complete inhibition at 1 nM
[(1E,3E)-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methylpenta-1,3-dien-1-yl]phosphonic acid
-
isozyme IMPDH II IC50: 506 nM
[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]phosphonic acid
-
isozyme IMPDH II IC50: 168 nM
[(2E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-methylbut-2-en-1-yl]phosphoramidic acid
-
isozyme IMPDH II IC50: above 0.001 mM
[(2S,5R)-5-(6-amino-7,8-dihydro-9H-purin-9-yl)oxolan-2-yl]methyl cyanate
-
[(3E)-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methylpent-3-en-1-yl]phosphonic acid
-
isozyme IMPDH II IC50: 96 nM
[(3E)-5-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methylpent-3-en-1-yl]phosphonic acid
-
isozyme IMPDH II IC50: 20 nM
[(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-en-1-yl]phosphonic acid
-
isozyme IMPDH II IC50: 86 nM
[2-chloro-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenoxy]acetic acid
{3-[N''-cyano-N'-(4-cyano-3-methoxyphenyl)carbamimidamido]phenoxy}acetic acid
-
(1H-naphtho[2,3-d]imidazol-2-yl)methyl 4-aminobenzoate
-
-
(1H-naphtho[2,3-d]imidazol-2-yl)methyl 4-aminobenzoate
-
-
(1H-naphtho[2,3-d]imidazol-2-yl)methyl 4-aminobenzoate
-
(2E)-3-furan-2-yl-N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]prop-2-enamide
-
isozyme IMPDH II IC50: 28 nM
(2E)-3-furan-2-yl-N-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]prop-2-enamide
-
(2E)-N-(4-chlorophenyl)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)but-2-enamide
-
-
(2E)-N-(4-chlorophenyl)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)but-2-enamide
-
(2R)-2-[(naphthalen-1-yl)oxy]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
Q21
(2R)-2-[(naphthalen-1-yl)oxy]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
Q21
(2R)-2-[(naphthalen-1-yl)oxy]-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
Q21
(2S)-2-(2,3-dichloroanilino)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
potent inhibitor
(2S)-2-(2,3-dichloroanilino)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
Q67
(2S)-2-(2,3-dichlorophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
(2S)-2-(2,3-dichlorophenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
-
(3S)-oxolan-3-yl {[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate
i.e. VX-148, structure-activity relationship analysis, overview
(3S)-oxolan-3-yl {[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[4-(trifluoromethyl)phenyl]hex-4-enamide
-
-
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-N-[4-(trifluoromethyl)phenyl]hex-4-enamide
-
(4E)-N-(2,3-dichlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-(2,3-dichlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-(3,4-dichlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-(3,4-dichlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-(4-chloro-3-methoxyphenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-(4-chloro-3-methoxyphenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-(4-chlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-(4-chlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-(4-chlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-N,4-dimethylhex-4-enamide
-
-
(4E)-N-(4-chlorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-N,4-dimethylhex-4-enamide
-
(4E)-N-(4-cyanophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-(4-cyanophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-(4-fluorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-(4-fluorophenyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
derivative of mycophenolic acid. IC50 value for K562 cells proliferation 2.1 microM; derivative of mycophenolic acid. IC50 value for K562 cells proliferation 2.1 microM
(4E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4,6-dimethoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4,6-dimethoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(4E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
-
(4E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enamide
-
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1,3,4-thiadiazol-2-yl)hex-4-enamide
14.50% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1,3,4-thiadiazol-2-yl)hex-4-enamide
4.59% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1,3,4-thiadiazol-2-yl)hex-4-enamide
-
29.44% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-1,2,4-triazol-5-yl)hex-4-enamide
46.13% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-1,2,4-triazol-5-yl)hex-4-enamide
98.87% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-1,2,4-triazol-5-yl)hex-4-enamide
-
42.79% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-tetrazol-5-yl)hex-4-enamide
22.99% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-tetrazol-5-yl)hex-4-enamide
3.59% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(1H-tetrazol-5-yl)hex-4-enamide
-
19.94% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(4H-1,2,4-triazol-4-yl)hex-4-enamide
14.29% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(4H-1,2,4-triazol-4-yl)hex-4-enamide
4.65% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(4H-1,2,4-triazol-4-yl)hex-4-enamide
-
32.43% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(pyridin-2-yl)hex-4-enamide
7.83% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(pyridin-2-yl)hex-4-enamide
2.36% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(pyridin-2-yl)hex-4-enamide
-
16.66% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(thiazol-2-yl)hex-4-enamide
22.27% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(thiazol-2-yl)hex-4-enamide
1.45% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methyl-N-(thiazol-2-yl)hex-4-enamide
-
17.11% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioic S-acid
11.56% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioic S-acid
3.03% inhibition at 0.001 mg
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioic S-acid
-
13.61% inhibition at 0.001 mg
(E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enamide
5.24% inhibition at 0.001 mg
(E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enamide
94.46% inhibition at 0.001 mg
(E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enamide
-
14.21% inhibition at 0.001 mg
(R,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
9.03% inhibition at 0.001 mg
(R,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
3.15% inhibition at 0.001 mg
(R,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
-
9.49% inhibition at 0.001 mg
(S,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
9.28% inhibition at 0.001 mg
(S,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
0.06% inhibition at 0.001 mg
(S,E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methyl-6-(oxiran-2-yl)-6-oxohex-2-en-1-yl)isobenzofuran-1(3H)-one
-
11.99% inhibition at 0.001 mg
1-[(3,4-dichlorophenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
-
-
1-[(3,4-dichlorophenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
0.1% inhibition at 0.01 mM
1-[(3,4-dichlorophenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
-
-
1-[(3,4-dichlorophenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
0.1% inhibition at 0.01 mM
1-[(3-chlorophenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
-
-
1-[(3-chlorophenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
0.1% inhibition at 0.01 mM
1-[(3-chlorophenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
-
-
1-[(3-chlorophenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
0.1% inhibition at 0.01 mM
1-[(3-methoxyphenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
-
-
1-[(3-methoxyphenyl)methyl]-4-[[(naphthalen-1-yl)oxy]methyl]-1H-1,2,3-triazole
30.66% inhibition at 0.01 mM
1-[(3-methoxyphenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
-
-
1-[(3-methoxyphenyl)methyl]-4-[[(naphthalen-2-yl)oxy]methyl]-1H-1,2,3-triazole
24.94% inhibition at 0.01 mM
1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate
-
-
1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate
binds in the nicotinamide subsite and does not interact with ADP
1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate
-
not inhibitory to wild-type
1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate
-
-
1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate
-
-
2-(1-naphthalenyloxy)-N-[(2-(4-pyridinyl)-5-benzoxazolyl)]-(2S)-propanamide
-
-
2-(1-naphthalenyloxy)-N-[(2-(4-pyridinyl)-5-benzoxazolyl)]-(2S)-propanamide
-
-
2-(1-naphthalenyloxy)-N-[(2-(4-pyridinyl)-5-benzoxazolyl)]-(2S)-propanamide
-
-
2-(1-naphthalenyloxy)-N-[(2-(4-pyridinyl)-5-benzoxazolyl)]-(2S)-propanamide
-
-
2-(4-methoxyphenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
2-(4-methoxyphenoxy)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide
-
-
2-([2-[2-(furan-2-yl)phenyl]-4-oxo-4H-1-benzopyran-3-yl]oxy)-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
-
2-([2-[2-(furan-2-yl)phenyl]-4-oxo-4H-1-benzopyran-3-yl]oxy)-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
0.1% inhibition at 0.01 mM
2-chloro-N,N-dimethyl-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]benzamide
noncompetitive inhibitor, that has similar affinity to both E-IMP and E-XMP, enzyme binding structure analysis, overview
2-chloro-N,N-dimethyl-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]benzamide
-
2-chloro-N-methyl-5-[[[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]amino]carbonyl]aminobenzamide
-
-
2-chloro-N-methyl-5-[[[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]amino]carbonyl]aminobenzamide
-
-
2-chloro-N-methyl-5-[[[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]amino]carbonyl]aminobenzamide
-
-
2-chloro-N-methyl-5-[[[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]amino]carbonyl]aminobenzamide
-
-
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
-
-
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
antagonizes ADP binding
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
-
-
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
-
not inhibitory to wild-type
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
-
-
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
-
2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide
-
-
2-[4-([1-[(3,4-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
-
-
2-[4-([1-[(3,4-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
0.1% inhibition at 0.01 mM
2-[4-([1-[(3-chlorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
-
-
2-[4-([1-[(3-chlorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
0.1% inhibition at 0.01 mM
2-[4-([1-[(3-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
-
-
2-[4-([1-[(3-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy)phenyl]-5-methyl-1,3,4-oxadiazole
0.1% inhibition at 0.01 mM
2-[[2-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
-
2-[[2-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
0.1% inhibition at 0.01 mM
2-[[2-(3,4-dimethoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
-
2-[[2-(3,4-dimethoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
34.45% inhibition at 0.01 mM
2-[[2-(3,4-dimethoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(naphthalen-1-yl)acetamide
-
-
2-[[2-(3,4-dimethoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(naphthalen-1-yl)acetamide
0.1% inhibition at 0.01 mM
2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
-
2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
56.81% inhibition at 0.01 mM
2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(naphthalen-1-yl)acetamide
-
-
2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(naphthalen-1-yl)acetamide
2.1% inhibition at 0.01 mM
2-[[2-(4-methylphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
-
2-[[2-(4-methylphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]-N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
0.1% inhibition at 0.01 mM
3,4-dihydro-3-methyl-4-oxo-N-(6,7,8,9-tetrahydro2-dibenzofuranyl)-1-phthalazineacetamide
-
-
3,4-dihydro-3-methyl-4-oxo-N-(6,7,8,9-tetrahydro2-dibenzofuranyl)-1-phthalazineacetamide
-
-
3,4-dihydro-3-methyl-4-oxo-N-(6,7,8,9-tetrahydro2-dibenzofuranyl)-1-phthalazineacetamide
-
-
3,4-dihydro-3-methyl-4-oxo-N-(6,7,8,9-tetrahydro2-dibenzofuranyl)-1-phthalazineacetamide
-
-
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
-
-
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
-
-
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
-
not inhibitory to wild-type
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
-
-
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
-
3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate
-
-
3-(2-[[(4-chlorophenyl)carbamoyl]amino]propan-2-yl)-N-hydroxybenzene-1-carboximidamide
P200
3-(2-[[(4-chlorophenyl)carbamoyl]amino]propan-2-yl)-N-hydroxybenzene-1-carboximidamide
P200
3-(2-[[(4-chlorophenyl)carbamoyl]amino]propan-2-yl)-N-hydroxybenzene-1-carboximidamide
P200
3-(4-chlorophenyl)-4-(4-ethoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
-
3-(4-chlorophenyl)-4-(4-ethoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
3-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)propyl (4-chlorophenyl)carbamate
-
-
3-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)propyl (4-chlorophenyl)carbamate
-
4-(3-bromo-4-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
-
4-(3-bromo-4-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
4-(4-acetamidophenyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
-
4-(4-acetamidophenyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
4-(4-acetamidophenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
-
4-(4-acetamidophenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
4-(5-bromo-2-fluorophenyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
-
4-(5-bromo-2-fluorophenyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
4-(5-bromo-2-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
-
4-(5-bromo-2-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid
-
4-acetyl-N-(3-chloro-4-fluorophenyl)-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide
-
-
4-acetyl-N-(3-chloro-4-fluorophenyl)-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide
-
4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinolin-2(1H)-one
A110
4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinolin-2(1H)-one
A110
4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinoline 1-oxide
Q81W29
-
4-[(1R)-1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]ethoxy]quinoline 1-oxide
-
-
4-[(1R)-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4yl]ethoxy]quinoline-1-oxide
-
-
4-[(1R)-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4yl]ethoxy]quinoline-1-oxide
-
-
4-[(1R)-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4yl]ethoxy]quinoline-1-oxide
-
-
4-[(1R)-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4yl]ethoxy]quinoline-1-oxide
-
-
6-((E)-4-(4-(adenosin-50-yl)methyl-1H-1,2,3-triazol-1-yl)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one
-
6-((E)-4-(4-(adenosin-50-yl)methyl-1H-1,2,3-triazol-1-yl)-3-methylbut-2-en-1-yl)-7-hydroxy-5-methoxy-4-methylisobenzofuran-1(3H)-one
-
uncompetitive versus IMP
6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate
-
covalent modification of the enzyme, total inactivation after 15 min at 0.01 mg/ml Cl-IMP, activity can be restored with 2-mercaptoethanol
6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate
-
50% inactivation after 90 min at 0.00012 mM Cl-IMP
6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate
-
-
6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate
-
acts at the IMP binding site
6-chloroinosine 5'-phosphate
-
-
6-chloroinosine 5'-phosphate
-
-
6-chloroinosine 5'-phosphate
-
6-Chloropurine ribonucleoside 5'-phosphate
-
inosine 5'-phosphate and guanosine 5'-phosphate retard inactivation
6-Chloropurine ribonucleoside 5'-phosphate
-
-
6-thioinosine 5'-phosphate
-
complete inactivation after 10 min preincubation at a concentration of 0.001 mM; in absence of glutathione
6-thioinosine 5'-phosphate
-
in absence of glutathione
7-amino-5-(4-chlorophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
-
-
7-amino-5-(4-chlorophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
-
7-amino-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
-
-
7-amino-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
-
7-amino-5-(5-nitrothiophen-2-yl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
-
-
7-amino-5-(5-nitrothiophen-2-yl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
-
9-(5-O-[hydroxy[([hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]oxy)methyl]phosphoryl]-beta-L-ribofuranosyl)-9H-purin-6-amine
inhibition of leukemia K562 cells proliferation, IC50 of 71.3 microM
9-(5-O-[hydroxy[([hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl]oxy)methyl]phosphoryl]-beta-L-ribofuranosyl)-9H-purin-6-amine
homology modeling; homology modeling
ADP
multiple inhibition with tiazofurin, competitive versus NAD+
ADP
binds in the adenosine portion, tiazofurin and ADP are strongly synergistic inhibitors, a conformational change occurs upon the binding of one inhibitor that increases the affinity of the second inhibitor
AMP
-
-
AMP
-
20% inhibition at high concentrations
ATP
-
at high concentration of IMP and KCl
benzamide riboside
-
NAD+ binding site inhibitor
benzamide riboside
displays skeletal muscle toxicity in preclinical trials, which limits its utility; displays skeletal muscle toxicity in preclinical trials, which limits its utility
benzamide riboside
inhibitory activity is higher than tiazofurin and lower than selenazofurin; inhibitory activity is higher than tiazofurin and lower than selenazofurin
beta-methylene thiazole 4-carboxamide adenine dinucleotide
-
i.e. beta-Me-TAD or CH2-TAD
beta-methylene thiazole 4-carboxamide adenine dinucleotide
-
i.e. beta-Me-TAD
BMS-337197
-
isozyme IMPDH II IC50: 16 nM
BMS-337197
-
i.e. BMS-337197
BMS-337197
-
IC50: 0.0082 mM
BMS-337197
-
is a potent IMPDH inhibitor, shows in vivo activity for inhibition of antibody production in mice
BMS-337197
-
is a potent IMPDH inhibitor, shows in vivo activity for inhibition of antibody production in the adjuvant-induced arthritis model in rats
C2-mycophenolic adenine dinucleotide
-
methylenephosphophosphonate analogue of mycophenolic adenine dinucleotide
C2-mycophenolic adenine dinucleotide
-
-
Ca2+
-
competitive inhibition with respect to both K+ and NAD+
Ca2+
-
29% inactivation in the presence of 0.1M K+
curcumin
-
significantly reduces the level of GTP and reduces the rate of cell growth
curcumin
0.1 mM, 68% inhibition, both competitive and uncompetitive
cyclohexyl[4-(isoquinoline-5-sulfonyl)piperazin-1-yl]methanone
-
uncompetitive inhibition with respect to IMP and NAD+
cyclohexyl[4-(isoquinoline-5-sulfonyl)piperazin-1-yl]methanone
VCC234718
EICARMP
-
-
eicosadienoic acid
competitive inhibitor versus IMPDH; competitive inhibitor versus IMPDH
eicosadienoic acid
-
competitive to inosine 5'-phosphate
GDP
-
GDP
-
45% inhibition at 0.6 mM
GMP
-
GMP
-
competitive, 58% inhibition at 0.5 mM
GMP
-
competitive with respect to IMP
GMP
-
competitive with respect to IMP and non competitive with respect to NAD+
GMP
-
competitive with respect to IMP
GMP
-
weak and competitive inhibition, strong binding, dissociation by 3 M urea
GMP
-
competitive with respect to IMP
GMP
-
competitive with respect to IMP, non competitive with respect to NAD+ and K+
GMP
-
competitive with respect to IMP
GMP
-
feedback inhibitor; feed-back inhibitor eliciting 'allosteric' kinetics of the enzyme, determination of the GMP binding site
GMP
-
55% inhibition at 0.6 mM
GTP
-
-
GTP
-
45% inhibition at 0.6 mM
imidazo[4,5-e][1,4]diazapine
-
-
imidazo[4,5-e][1,4]diazapine
-
fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition
imidazo[4,5-e][1,4]diazapine
-
-
imidazo[4,5-e][1,4]diazapine
fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition; fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition
iodoacetate
-
-
iodoacetate
-
98% inhibition at 10 mM
Li+
-
Li+
-
competitive inhibition with respect to both K+ and NAD+
Li+
-
inhibits stimulatory effect of K+
linoleic acid
-
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
-
-
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
antagonizes ADP binding
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
-
-
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
-
not inhibitory to wild-type
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
-
-
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
-
methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
-
-
Mg2+
-
inhibits K+ activation
Mg2+
-
competitive inhibition with respect to both K+ and NAD+
Mg2+
-
inhibits K+ activation
Mg2+
-
inhibits K+ activation
mizoribine
-
-
mizoribine
competitive inhibitor
mizoribine 5'-phosphate
competitive versus NAD+, slow tight-binding, the mutant A251T is 20fold more sesitive
mizoribine 5'-phosphate
-
complexes the enzyme
mizoribine monophosphate
-
-
mizoribine monophosphate
-
-
mizoribine monophosphate
-
-
mizoribine monophosphate
-
-
mizoribine monophosphate
-
-
mycophenolate mofetil
-
NAD+ binding site inhibitor
mycophenolate mofetil
-
-
mycophenolate mofetil
-
prodrug of mycophenolic acid, treatment of diet-induced obese mice with mycophenolate mofetil for 28 days does not affect food intake or lean body mass but reduces body fat content (by 36%), adipocyte size and number and the appearance of hepatic steatosis
Mycophenolic acid
inhibitory to enzyme, also inhibits growth of Babesia gibsoni cells. The treated parasite cultures have predominantly single Babesia cells as opposed to untreated cells that have both single and dividing forms as observed on day two
Mycophenolic acid
Q81W29
noncompetitive with regard to inosine monophosphate and NAD+
Mycophenolic acid
-
uncompetitive with respect to IMP and NAD+
Mycophenolic acid
inhibition of the wild-type enzyme uncompetitively versus NAD+, the mutant A251T enzyme is 4fold more resistant to mycophenolic acid
Mycophenolic acid
-
uncompetitive
Mycophenolic acid
subtype MMRL2651 of Cryptococcus gattii is naturally resistant to inhibition by mycophenolic acid
Mycophenolic acid
-
50% inhibition at 0.0003 mM, reversible by guanine
Mycophenolic acid
-
50% inhibition at 0.00025 mM, human plasma or serum reduces the inhibition
Mycophenolic acid
-
mutants have increased Ki for MPA
Mycophenolic acid
-
type II enzyme is 4.8fold more sensitive than type I
Mycophenolic acid
-
key binding interactions for the benzofuranone residue mycophenolic acid and the N-[3-methoxy-4-(5-oxazolyl)phenyl] fragment of VX-497, the benzofuranone ring mycophenolic acid binds in a spatially restricted region of the NAD+ binding site packing with the hypoxanthine ring xanthosine 5'-phosphate, the carbonyl oxygen and hydroxy residues are involved in a hydrogen bond array that involves Gly326, Thr333 and Gln441, the appending methyl substituent of the benzofuranone system, resides in a small hydrophobic pocket defined by the planes of Asn303 amide and Arg322 guanidine, the phenyl oxazole moiety of VX-497 binds in the same region as the benzofuranone ring of mycophenolic acid, forming hydrogen bonds between the oxazole nitrogen and oxygen with Gly326 and possibly Thr333, respectively, the methoxy residue binds in the same pocket as the benzofuranone methyl in mycophenolic acid
Mycophenolic acid
-
isozyme IMPDH II IC50: 15 nM
Mycophenolic acid
-
potent, uncompetitive, reversible, inhibits both isozymes, prodrug is mycophenolate mofetil, isozyme IMPDH II IC50: 14 nM
Mycophenolic acid
-
potent, uncompetitive, reversible, inhibits both isozymes, prodrug is mycophenolate mofetil
Mycophenolic acid
-
isozyme IMPDH II IC50: 11 nM, potent, uncompetitive inhibition, immunosuppressive drug, prodrug is mycophenolate mofetil
Mycophenolic acid
-
enzyme inhibition by mycophenolic acid impairs maturation and function of dendritic cells
Mycophenolic acid
-
traps the reaction intermediate E-XMP, the human enzyme is sensitive to the inhibitor due to its open dehydrogenase conformation
Mycophenolic acid
-
uncompetitive inhibition, the interaction with the enzyme, inducing striking conformational changes and aggregation, is regulated by GTP, GTP reverses the enzyme aggregation by inhibitor mycophenolic acid, the inhibitor is part of an immunosuppressive drug
Mycophenolic acid
-
IC50: 99.2 nM with umbilical vein endothelial cells, 128 nM with Jurkat cells, inhibits the enzyme in vivo and in vitro, mycophenolic acid inhibits tumor-associated angiogenesis and is used as clinical drug in immunosuppression
Mycophenolic acid
-
exerts immunosuppression through inhibition of the enzyme in lymphocytes, inhibitory potency in vivo, overview, prodrug is mycophenolate mofetil
Mycophenolic acid
-
comparison with inhibition of histone deacetylase and K562 cell proliferation
Mycophenolic acid
-
biphasic concentration-dependent influence on inosine 5'-phosphate dehydrogenase basal activity. At concentrations around or below IC50 value, mycophenolic acid increases the basal enzymic activity, associated with elevated expression of isoform IMPDH2. Despite increased expression, the basal enzyme activity decreases following exposure to high mycophenolic acid concentrations
Mycophenolic acid
-
uncompetitive inhibition
Mycophenolic acid
-
IMPDH activity in erythrocytes is inhibited at the peak plasma concentration of mycophenolic acid in initial kidney transplant recipients. Reduction does not coincide with the peak of the plasma concentration of phenolic and acyl glucuronides of mycophenolic acid
Mycophenolic acid
is a uncompetitive inhibitor of IMPDH with respect to both inosine 5'-phosphate and NAD+, inhibits IMPDH by trapping the covalent intermediate. It it is easily converted to mycophenolic acid-7-O-glucuronide, which limits the inhibitory efficacy and higher doses are therefore needed in order to maintain appropriate therapeutic levels; is a uncompetitive inhibitor of IMPDH with respect to both inosine 5'-phosphate and NAD+, inhibits IMPDH by trapping the covalent intermediate. It it is easily converted to mycophenolic acid-7-O-glucuronide, which limits the inhibitory efficacy and higher doses are therefore needed in order to maintain appropriate therapeutic levels
Mycophenolic acid
-
new enzymatic mycophenolic acid assay, cross-reactivity by mycophenolic acid-acyl-glucuronide is less than 5%, thus interference is expected to be clinically irrelevant
Mycophenolic acid
inhibition of leukemia K562 cells proliferation, IC50 of 7.7 microM; inhibition of leukemia K562 cells proliferation, IC50 of 7.7 microM
Mycophenolic acid
a natural product and a reversible, potent and uncompetitive inhibitor of IMPDH
Mycophenolic acid
reversible, potent, uncompetitive inhibitor, 99.9% inhibition at 0.01 mM
Mycophenolic acid
-
mixed type inhibition
Mycophenolic acid
-
in 3T3-L1 preadipocytes inhibition of IMPDH with mycophenolic acid reduces intracellular GTP levels by 60% (p <0.05) and blocks adipogenesis. Co-treatment with guanosine restores GTP levels and adipogenesis
Mycophenolic acid
complete inhibition at 0.01 mM, 83% inhibition at 0.05 mM
Mycophenolic acid
-
50% inhibition at 0.024 mM
Mycophenolic acid
-
IMD2 imparts mycophenolic acid resistance due to A253S as a critical amino acid substitution
Mycophenolic acid
uncompetitive to NAD+
Mycophenolic acid
-
i.e. MPA, slight inhibition, microbial IMPDHs differ from mammalian enzymes in their lower affinity for inhibitors such as mycophenolic acid and thiazole-4-carboxamide adenine dinucleotide, part of this resistance is determined by the coupling between nicotinamide and adenosine subsites in the NAD+ binding site that is postulated to involve an active site flap
Mycophenolic acid
82.99% inhibition at 0.001 mg, inhibits the enzyme activity and leads to complete inhibition of proliferation of Trypanosoma at below 0.001 mM. Mycophenolic acid derivatives can act as trypanocidal drugs with trypanocidal activity
Mycophenolic acid
99.60% inhibition at 0.001 mg, inhibits the enzyme activity and leads to complete inhibition of proliferation of Trypanosoma at below 0.001 mM. Mycophenolic acid derivatives can act as trypanocidal drugs with trypanocidal activity
Mycophenolic acid
-
90.53% inhibition at 0.001 mg, inhibits the enzyme activity and leads to complete inhibition of proliferation of Trypanosoma at below 0.001 mM. Mycophenolic acid derivatives can act as trypanocidal drugs with trypanocidal activity
mycophenolic acid-acyl-glucuronide
-
uncompetitive inhibition, is a weaker inhibitor of IMPDH II than mycophenolic acid. When coincubated with mycophenolic acid, mycophenolic acid-acyl-glucuronide activity is negligible at pharmacological concentrations
mycophenolic acid-acyl-glucuronide
-
cross-reactivity by mycophenolic acid is less than 5%, thus interference is expected to be clinically irrelevant
N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-([4-oxo-2-[2-(thiophen-2-yl)phenyl]-4H-1-benzopyran-3-yl]oxy)acetamide
-
-
N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-([4-oxo-2-[2-(thiophen-2-yl)phenyl]-4H-1-benzopyran-3-yl]oxy)acetamide
0.1% inhibition at 0.01 mM
N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-[[4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-3-yl]oxy]acetamide
-
-
N-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-[[4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-3-yl]oxy]acetamide
0.1% inhibition at 0.01 mM
N-(2-{3-[(1E)-N-(2-aminoethoxy)ethanimidoyl]phenyl}propan-2-yl)-N'-(4-chloro-3-nitrophenyl)urea
an inhibitor with in vivo anticryptosporidial activity, binding structure determination and analysi, P131 contains two aromatic groups, one of which interacts with the hypoxanthine ring of IMP, while the second interacts with the aromatic ring of a tyrosine in the adjacent subunit. In addition, the amine and NO2 moieties bind in hydrated cavities, forming water-mediated hydrogen bonds to the proteins. The oxime group of P131 lies across the hypoxanthine ring of IMP, while the N5 amine forms hydrogen bonds to the main chain carbonyl O atom of Gly212 and N3 of IMP in all of the subunits
N-(2-{3-[(1E)-N-(2-aminoethoxy)ethanimidoyl]phenyl}propan-2-yl)-N'-(4-chloro-3-nitrophenyl)urea
-
P131
N-(2H-indazol-6-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide
TBK6
N-(2H-indazol-6-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide
TBK6
N-(4-bromophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide
crystallization data. Poor inhibition of human IMPDH2
N-(4-bromophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide
-
N-(4-bromophenyl)-2-[2-(1,3-thiazol-2-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(4-bromophenyl)-2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]acetamide
-
-
N-(4-bromophenyl)-2-[[2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]acetamide
0.1% inhibition at 0.01 mM
N-(4-bromophenyl)-2-[[2-(4-methylphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]acetamide
-
-
N-(4-bromophenyl)-2-[[2-(4-methylphenyl)-4-oxo-4H-1-benzopyran-3-yl]oxy]acetamide
0.1% inhibition at 0.01 mM
N-(4-bromophenyl)-N-[(1-methylethenyl)phenyl]ethyl urea
-
-
N-(4-bromophenyl)-N-[(1-methylethenyl)phenyl]ethyl urea
-
-
N-(4-bromophenyl)-N-[(1-methylethenyl)phenyl]ethyl urea
-
-
N-(4-bromophenyl)-N-[(1-methylethenyl)phenyl]ethyl urea
-
-
N-(4-bromophenyl)-N-[1-[3-[1-(hydroxyimino)ethyl]phenyl]-1-methylethyl] urea
-
-
N-(4-bromophenyl)-N-[1-[3-[1-(hydroxyimino)ethyl]phenyl]-1-methylethyl] urea
-
-
N-(4-bromophenyl)-N-[1-[3-[1-(hydroxyimino)ethyl]phenyl]-1-methylethyl] urea
-
-
N-(4-bromophenyl)-N-[1-[3-[1-(hydroxyimino)ethyl]phenyl]-1-methylethyl] urea
-
-
N-(4-chloro-3-methoxyphenyl)-2-(4-oxo[1]benzopyrano[4,3-c]pyrazol-1(4H)-yl)acetamide
-
N-(4-chloro-3-methoxyphenyl)-2-(4-oxo[1]benzopyrano[4,3-c]pyrazol-1(4H)-yl)acetamide
-
-
N-(4-chlorophenyl)-2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
-
N-(4-chlorophenyl)-2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)acetamide
-
N-(4-chlorophenyl)-2-phenoxypropanamide
antagonizes ADP binding
N-(4-chlorophenyl)-2-phenoxypropanamide
-
-
N-(4-chlorophenyl)-2-phenoxypropanamide
-
-
N-(4-chlorophenyl)-2-phenoxypropanamide
-
N-(4-chlorophenyl)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)butanamide
-
-
N-(4-chlorophenyl)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)butanamide
-
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
-
-
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
binds in the nicotinamide subsite and does not interact with ADP
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
-
-
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
-
not inhibitory to wild-type
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
-
-
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
-
N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
-
-
N-(4-methoxyphenyl)-2-(naphthalen-1-yl)acetamide
-
-
N-(4-methoxyphenyl)-2-(naphthalen-1-yl)acetamide
-
-
N-(4-methoxyphenyl)-2-(naphthalen-1-yl)acetamide
-
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
binds in the nicotinamide subsite and does not interact with ADP
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
not inhibitory to wild-type
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-1-yl)-2-[(4-oxo-2-phenyl-4H-1-benzopyran-3-yl)oxy]acetamide
-
-
N-(naphthalen-1-yl)-2-[(4-oxo-2-phenyl-4H-1-benzopyran-3-yl)oxy]acetamide
0.1% inhibition at 0.01 mM
N-(naphthalen-1-yl)-2-[[4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-3-yl]oxy]acetamide
-
-
N-(naphthalen-1-yl)-2-[[4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-1-benzopyran-3-yl]oxy]acetamide
16.54% inhibition at 0.01 mM
N-(naphthalen-2-yl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
poor inhibition of human IMPDH2
N-(naphthalen-2-yl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
Q81W29
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
C91
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
C91
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
C91
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
C91, 0.197% inhibition at 0.01 mM
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide
-
not inhibitory to wild-type
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide
-
-
N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide
-
-
N-[2-chloro-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenyl]-beta-D-xylofuranosylamine
P176; P221
N-[2-chloro-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenyl]-beta-D-xylofuranosylamine
P176; P221
N-[4-(1-benzyl-2,4,6-trioxo-2,3,4,5,6,11-hexahydro-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidin-5-yl)phenyl]acetamide
-
-
N-[4-(1-benzyl-2,4,6-trioxo-2,3,4,5,6,11-hexahydro-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidin-5-yl)phenyl]acetamide
-
N-[4-chloro-3-(alpha-D-ribofuranosyloxy)phenyl]-N'-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]urea
P178
N-[4-chloro-3-(alpha-D-ribofuranosyloxy)phenyl]-N'-[2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]urea
P178
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(1R,2S)-2-[(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]-1-methylcyclopropyl]propanamide
-
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(1R,2S)-2-[(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]-1-methylcyclopropyl]propanamide
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(1S,2R)-2-[(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]-1-methylcyclopropyl]propanamide
-
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(1S,2R)-2-[(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]-1-methylcyclopropyl]propanamide
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhexanamide
-
-
N-[4-chloro-3-(trifluoromethyl)phenyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhexanamide
-
N-[4-chloro-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-N'-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
P182
N-[4-chloro-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-N'-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
P182
N-[4-chloro-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-N'-(2-[3-[(1E)-N-hydroxyethanimidoyl]phenyl]propan-2-yl)urea
P182
N2-(2,3-dichlorophenyl)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]-L-alaninamide
a competitive inhibitor versus NAD+, that has a strong preference for E-IMP, enzyme binding structure analysis, overview
N2-(2,3-dichlorophenyl)-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]-L-alaninamide
-
Na+
-
Na+
-
competitive inhibition with respect to both K+ and NAD+
NAD+
Q81W29
-
NAD+
-
substrate inhibition
NAD+
-
substrate inhibition at high concentration
NAD+
-
substrate inhibition
NAD+
-
substrate inhibition
NAD+
substrate inhibition
NAD+
-
at high concentration, inhibition of canonical isoform. No inhibition of retinal-specific isoforms
NAD+
-
substrate inhibition at high concentration
NAD+
low substrate inhibition
NAD+
substrate inhibition
NAD+
-
substrate inhibition at high concentration
NAD+
-
50% inhibition at 0.62 mM
NAD+
-
44% inhibition at 1.5 M
NAD+
substrate inhibition
NAD+
-
substrate inhibition
NADH
-
-
NADH
-
mixed inhibition type versus inosine 5'-phosphate and NAD+
NADH
-
non competitive with respect to K+, IMP and NAD
NADH
-
poor inhibitor, product inhibition, non competitive
NADH
-
non competitive with respect to NAD+
NADH
product inhibition, noncompetitive versus IMP, NAD+, and K+
NADH
-
uncompetitive versus inosine 5'-phosphate and mixed inhibition type versus NAD+
oxanosine monophosphate
potent reversible competitive inhibitor
oxanosine monophosphate
-
oxanosine monophosphate
potent reversible competitive inhibitor
oxanosine monophosphate
-
potent reversible competitive inhibitor
oxanosine monophosphate
potent reversible competitive inhibitor
oxanosine monophosphate
-
potent reversible competitive inhibitor
p-chloromercuribenzoate
-
100% inhibition at 0.021 mM
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
inhibition can be restored by addition of DTT
P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate
-
-
P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate
-
-
P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate
-
-
P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate
-
-
P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate
-
-
P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(2-ethyladenosin-5'-yl)methylenebis(phosphonate)
-
P1-[7-hydroxy-6-(hydroxyethyl)-5-methoxy-4-methylphthtalan-1-one-2-yl]-P2-(2-ethyladenosin-5'-yl)methylenebis(phosphonate)
-
-
Pentamidine
complete inhibition at 500 ng/ml
Pentamidine
complete inhibition at 500 ng/ml
Pentamidine
-
complete inhibition at 500 ng/ml
ribavirin
-
-
ribavirin
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, a prodrug of corresponding 5-monophosphate, which as a competitive inhibitor interacts with the IMP domain of IMPDH; 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, a prodrug of corresponding 5-monophosphate, which as a competitive inhibitor interacts with the IMP domain of IMPDH
ribavirin
competitive inhibitor
ribavirin
Parainfluenza virus
-
potent competitive inhibition, shows anti-viral activity in vivo, detailed overview
ribavirin
-
potent competitive inhibition, shows anti-viral activity in vivo, detailed overview
ribavirin 5'-monophosphate
-
-
ribavirin 5'-monophosphate
-
competitive with respect to IMP
ribavirin 5'-monophosphate
-
-
ribavirin 5'-monophosphate
-
ribavirin 5'-monophosphate
-
ribavirin 5'-phosphate
-
-
ribavirin 5'-phosphate
-
-
ribavirin monophosphate
-
-
ribavirin monophosphate
-
-
ribavirin monophosphate
-
ribavirin monophosphate
-
-
ribavirin monophosphate
-
-
ribavirin monophosphate
-
-
S-(prop-1-en-2-yl) (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioate
16.47% inhibition at 0.001 mg
S-(prop-1-en-2-yl) (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioate
6.51% inhibition at 0.001 mg
S-(prop-1-en-2-yl) (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enethioate
-
12.79% inhibition at 0.001 mg
Selenazofurin
-
inhibition (in vivo) by the NAD analog formed intracellularly
Selenazofurin
Parainfluenza virus
-
potent competitive inhibition, shows anti-viral activity in vivo, detailed overview, a complete reversal of the antiviral activity of selenazofurin was obtained by addition of guanosine and selenazofurin at varying concentrations
Selenazofurin
-
potent competitive inhibition, shows anti-viral activity in vivo, detailed overview
tetrasodium 6,6'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(E)-diazene-2,1-diyl]]bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
-
-
tetrasodium 6,6'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(E)-diazene-2,1-diyl]]bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
-
thiazole-4-carboxamide adenine dinucleotide
-
uncompetitive with respect to IMP and NAD
thiazole-4-carboxamide adenine dinucleotide
-
-
thiazole-4-carboxamide adenine dinucleotide
-
inhibition is strong and not reversible by NAD+; thiazole-4-carboxamide adenine dinucleotide acts non competitive
thiazole-4-carboxamide adenine dinucleotide
-
reversible inhibition
thiazole-4-carboxamide adenine dinucleotide
-
i.e. TAD, mixed inhibition type versus inosine 5'-phosphate and NAD+
thiazole-4-carboxamide adenine dinucleotide
-
inhibitory mechanism
thiazole-4-carboxamide adenine dinucleotide
-
i.e. TAD, synthesis, noncompetitive inhibition, conformational analysis, and biological activity of inhibitor analogues, overview, TAD binds to the NAD+ binding site with out isozyme specificity, mechanism and molecular modeling using the enzyme crystal structure, overview, cytotoxic against K562 tumor cells
thiazole-4-carboxamide adenine dinucleotide
inhibition of leukemia K562 cells proliferation, IC50 of 3.7 microM; inhibition of leukemia K562 cells proliferation, IC50 of 3.7 microM
thiazole-4-carboxamide adenine dinucleotide
-
-
thiazole-4-carboxamide adenine dinucleotide
-
i.e. TAD, uncompetitive versus inosine 5'-phosphate and mixed inhibition type versus NAD+
thiazole-4-carboxamide adenine dinucleotide
-
i.e. TAD, slight inhibition, microbial IMPDHs differ from mammalian enzymes in their lower affinity for inhibitors such as mycophenolic acid and thiazole-4-carboxamide adenine dinucleotide, part of this resistance is determined by the coupling between nicotinamide and adenosine subsites in the NAD+ binding site that is postulated to involve an active site flap
tiazofurin
multiple inhibition with ADP, noncompetitive versus NAD+
tiazofurin
-
decrease of cell growth
tiazofurin
-
i.e. 2-beta-D-ribofuranosyl-thiazole-4-carboxamide, overview: clinical and molecular impact of inhibition; the drug is tested in clinical use to treat acute myelocytic leukemia, AML, detailed overview, tiazofurin treatment may result in induced differentiation of leukemic leukocytes in patients, incubation of K-562 cells with tiazofurin produces inhibition of IMP DH and decreases GTP concentration, these biochemical alterations are followed by a decrease in the expression of as proto-oncogene which is followed by induced differentiation of these cells, biochemical mechanism, overview
tiazofurin
-
noncompetitive inhibition, cytotoxic against K562 tumor cells
tiazofurin
competitive inhibitor
tiazofurin
Parainfluenza virus
-
-
tiazofurin
-
inhibits cell proliferation of hepatoma cells, overview
tiazofurin
binds in the nicotinamide portion of the dinucleotide site, tiazofurin and ADP are strongly synergistic inhibitors, a conformational change occurs upon the binding of one inhibitor that increases the affinity of the second inhibitor
VX-148
-
isozyme IMPDH II IC50: 6 nM
VX-148
has immunosuppressive activity; has immunosuppressive activity
VX-497
-
key binding interactions for the benzofuranone residue mycophenolic acid and the N-[3-methoxy-4-(5-oxazolyl)phenyl] fragment of VX-497, the benzofuranone ring mycophenolic acid binds in a spatially restricted region of the NAD+ binding site packing with the hypoxanthine ring xanthosine 5'-phosphate, the carbonyl oxygen and hydroxy residues are involved in a hydrogen bond array that involves Gly326, Thr333 and Gln441, the appending methyl substituent of the benzofuranone system, resides in a small hydrophobic pocket defined by the planes of Asn303 amide and Arg322 guanidine, the phenyl oxazole moiety of VX-497 binds in the same region as the benzofuranone ring of mycophenolic acid, forming hydrogen bonds between the oxazole nitrogen and oxygen with Gly326 and possibly Thr333, respectively, the methoxy residue binds in the same pocket as the benzofuranone methyl in mycophenolic acid
VX-497
-
isozyme IMPDH II IC50: 11 nM
xanthosine 5'-phosphate
Q81W29
competitive with regard to inosine monophosphate
xanthosine 5'-phosphate
-
39% competitive, inhibition at 0.5 mM
xanthosine 5'-phosphate
-
competitive with respect to IMP
xanthosine 5'-phosphate
-
-
xanthosine 5'-phosphate
-
competitive versus inosine 5'-phosphate but noncompetitive versus NAD+
xanthosine 5'-phosphate
-
-
xanthosine 5'-phosphate
-
competitive with respect to IMP
xanthosine 5'-phosphate
-
-
xanthosine 5'-phosphate
-
non-competitive with respect to NAD
xanthosine 5'-phosphate
-
competitive with respect to IMP, non competitive with respect to NAD and K+
xanthosine 5'-phosphate
-
product inhibitor
xanthosine 5'-phosphate
-
competitive inhibition
xanthosine 5'-phosphate
-
competitive with respect to IMP
xanthosine 5'-phosphate
-
competitive inhibition
xanthosine 5'-phosphate
-
competitive versus inosine 5'-phosphate but noncompetitive versus NAD+
xanthosine 5'-phosphate
-
-
xanthosine 5'-phosphate
-
-
XMP
product inhibition
XMP
product inhibition, competitive versus IMP, noncompetitive versus NAD+ and K+
[2-chloro-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenoxy]acetic acid
P225
[2-chloro-5-[([2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl]carbamoyl)amino]phenoxy]acetic acid
P225
additional information
-
the enzyme is not inhibited by mycophenolic acid
-
additional information
-
inhibitor synthesis and binding structure to the enzyme determined with the CBS deletion mutant enzyme variants, overview
-
additional information
-
-
-
additional information
-
overview
-
additional information
-
inhibitor synthesis and binding structure to the enzyme determined with the CBS deletion mutant enzyme variant, overview
-
additional information
-
inhibitor synthesis and binding structure to the enzyme determined with the CBS deletion mutant enzyme variant, overview
-
additional information
-
1,2,3-triazole containing ether IMPDH inhibitors, small alkyl group on the alpha-position of the ether is required, with the (R)-enantiomer significantly more active than the (S)-enantiomer. Electron-withdrawing groups in the 3- and/or 4-positions of the pendent phenyl ring are best, and conversion of the quinoline containing inhibitors to quinoline-N-oxides retains inhibitory activity both in the presence and absence of bovine serum albumin
-
additional information
-
overview
-
additional information
-
dinucleotide analogs of NAD
-
additional information
-
overview
-
additional information
-
no enzyme inhibition by nucleic acids
-
additional information
-
compounds are not inhibitory to Escherichia coli, Tritrichomonas foetus, and Leishmania donovani IMPDH. Susceptible enzymes are defined by structural motif A165/Y358, Cryptosporidium parvum numbering
-
additional information
-
inhibition by purine and pyrimidine compounds
-
additional information
-
mycophenolic acid and it's nuclear variants
-
additional information
-
-
-
additional information
-
overview
-
additional information
-
6-ethoxycarbonyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0.]hexane-2,4-diones inhibit type II enzyme
-
additional information
-
no enzyme inhibition by nucleic acids
-
additional information
-
determination and analysis of structure-activity relationships of the different inhibitor molecules, overview
-
additional information
-
development and synthesis of inhibitors, determination and analysis of structure-activity relationships of the different inhibitor molecules with isozyme IMPDH II, overview
-
additional information
-
optimization of nitrile containing drugs, such as VX-148, by combining them with an oxazole moiety which is very reactive in inhibition, overview
-
additional information
-
synthesis, inhibitory potency, and structure-activity relationship of enzyme with phosphonic acid-containing analogues of mycophenolic acid inhibitors, IC50 values, overview
-
additional information
-
the enzyme is resistant to mizoribine 5'-phosphate due to its open dehydrogenase conformation in opposite to the bacterial enzyme which has a closed hydrolase conformation
-
additional information
-
inhibitor development and synthesis, overview
-
additional information
-
inhibition of the enzyme in K562 cells sensitizes the before resistant cells to methotrexate
-
additional information
-
retinal isoforms do not bind significant fractions of a random pool of oligonucleotides
-
additional information
IMPDH2 interacts with protein kinase B/Akt via its plekstrin homology domain, the resulting phosphorylation reduces activity
-
additional information
IMPDH2 interacts with protein kinase B/Akt via its plekstrin homology domain, the resulting phosphorylation reduces activity
-
additional information
-
mycophenolic acid-phenyl-glucuronide has no effect
-
additional information
involvement of three conserved water molecules (W(L), W(M), and W(C)) in the recognition of catalytic residues (R 322, D 364, and N 303) to inhibitor
-
additional information
-
involvement of three conserved water molecules (W(L), W(M), and W(C)) in the recognition of catalytic residues (R 322, D 364, and N 303) to inhibitor
-
additional information
-
IMPDH activity decreases more than 10% with increasing contamination by erythrocytes due to increasing AMP and protein content. Storage of lithium heparin blood samples at room temperature for 24 hours before peripheral blood mononuclear cell isolation does not lead to any significant changes in the IMPDH activity, when the activity is normalized to the AMP concentration
-
additional information
synthesis of mycophenolic acid derivatives as inhibitors. Functional groups at C5, C7, and C6' positions in mycophenolic acid are important for inhibitory activity against IMPDH. It is difficult to improve specificity against IMPDH II by modification of 5-, 7-, and 6'-group. Demethylation of 5-OMe results in increasing hydrophilicity, and lowering cell permeability. Ester bonds of protective groups at C7 and C6' positions are hydrolyzed to give mycophenolic acid in cultures, the effects of a tubulin-specific histone deacetylase inhibitor on proliferation and differentiation are weaker than its inhibitory activity against IMPDH; synthesis of mycophenolic acid derivatives as inhibitors. Functional groups at C5, C7, and C6' positions in mycophenolic acid are important for inhibitory activity against IMPDH. It is difficult to improve specificity against IMPDH II by modification of 5-, 7-, and 6'-group. Demethylation of 5-OMe results in increasing hydrophilicity, and lowering cell permeability. Ester bonds of protective groups at C7 and C6' positions are hydrolyzed to give mycophenolic acid in cultures, the effects of a tubulin-specific histone deacetylase inhibitor on proliferation and differentiation are weaker than its inhibitory activity against IMPDH
-
additional information
synthesis of mycophenolic acid derivatives as inhibitors. Functional groups at C5, C7, and C6' positions in mycophenolic acid are important for inhibitory activity against IMPDH. It is difficult to improve specificity against IMPDH II by modification of 5-, 7-, and 6'-group. Demethylation of 5-OMe results in increasing hydrophilicity, and lowering cell permeability. Ester bonds of protective groups at C7 and C6' positions are hydrolyzed to give mycophenolic acid in cultures, the effects of a tubulin-specific histone deacetylase inhibitor on proliferation and differentiation are weaker than its inhibitory activity against IMPDH; synthesis of mycophenolic acid derivatives as inhibitors. Functional groups at C5, C7, and C6' positions in mycophenolic acid are important for inhibitory activity against IMPDH. It is difficult to improve specificity against IMPDH II by modification of 5-, 7-, and 6'-group. Demethylation of 5-OMe results in increasing hydrophilicity, and lowering cell permeability. Ester bonds of protective groups at C7 and C6' positions are hydrolyzed to give mycophenolic acid in cultures, the effects of a tubulin-specific histone deacetylase inhibitor on proliferation and differentiation are weaker than its inhibitory activity against IMPDH
-
additional information
-
tacrolimus, cyclosporine and prednisolone do not affect IMPDH activity
-
additional information
structure- and ligand-based IMPDH inhibitor development, molecular modeling studies, overview
-
additional information
-
structure- and ligand-based IMPDH inhibitor development, molecular modeling studies, overview
-
additional information
inhibitor synthesis, analysis and comparison of potencies against isozymes IMPDH1 and IMPDH2, overview; inhibitor synthesis, analysis and comparison of potencies against isozymes IMPDH1 and IMPDH2, overview
-
additional information
inhibitor synthesis, analysis and comparison of potencies against isozymes IMPDH1 and IMPDH2, overview; inhibitor synthesis, analysis and comparison of potencies against isozymes IMPDH1 and IMPDH2, overview
-
additional information
enzyme cytoophidia are catalytically active and resistant to GDP allosteric inhibition
-
additional information
-
enzyme cytoophidia are catalytically active and resistant to GDP allosteric inhibition
-
additional information
-
-
-
additional information
no inhibition by tiazofurin and benzamide
-
additional information
-
no inhibition by tiazofurin and benzamide
-
additional information
-
-
-
additional information
-
not inhibitory: linoelaidic acid, methyl linoleate, cis-9-octadecen-1-ol
-
additional information
not inhibitory: resveratrol, genistein, eugenol, gingerol, naringenin, naringin, caffeic acid, morin, kaempferol, hesperidin, rosmarinic acid
-
additional information
IMPDH has multiple active site states that can be targeted for inhibitor design, and both the IMP/XMP and cofactor binding sites are exploited for that purpose, inhibitor screening of compounds with antitubercular activity, overview. Mechanism of MtbIMPDH2DELTACBS enzyme mutant inhibition
-
additional information
-
IMPDH has multiple active site states that can be targeted for inhibitor design, and both the IMP/XMP and cofactor binding sites are exploited for that purpose, inhibitor screening of compounds with antitubercular activity, overview. Mechanism of MtbIMPDH2DELTACBS enzyme mutant inhibition
-
additional information
several inhibitors compete with the flap for the vacant NADH site, thus preventing the hydrolysis of E-XMP* reaction intermediate
-
additional information
-
the enzyme is not inhibited by mycophenolic acid
-
additional information
-
inhibition by products and antimetabolites
-
additional information
-
overview
-
additional information
no inhibition by tiazofurin and seleno-thiazofurin
-
additional information
-
no inhibition by tiazofurin and seleno-thiazofurin
-
additional information
-
-
-
additional information
-
overview
-
additional information
-
no enzyme inhibition by nucleic acids
-
additional information
-
structural basis of the drug selectivity, overview
-
additional information
becomes resistant to IMPDH inhibitors by rearranging its purine salvage pathways to rely on xanthine instead of hypoxanthine
-
additional information
-
inhibitor synthesis, overview
-
additional information
-
the enzyme is not affected by allantoin, allantoic acid, uric acid, inosine, xanthosine, and xanthosine 5'-phosphate
-